

Supporting Information for:

Low catalyst loading enabled organocatalytic synthesis of chiral *bis*-heterocyclic frameworks containing pyrazole and isoxazole

Banni Preet Kaur^a, Vivek Sharma^a, Subhash Chandra Sahoo^b, Swapandeep Singh Chimni^a

^aDepartment of Chemistry, U.G.C. Centre of Advance Studies in Chemistry, Guru Nanak Dev University, Amritsar-143001, India; E-mail: sschimni@yahoo.com, sschimni.chem@gndu.ac.in.

^bDepartment of Chemistry, Panjab University, Chandigarh-160014.

Table of Contents

General Information	2
Experimental details and characterisation data	3-19
Single crystal X-ray diffraction analysis and crystal data	20-25
Copies of NMR Spectra	26-87
Copies of HPLC chromatogram	88-148


General Information

All the reactions were performed in oven-dried glassware. All solvents and commercially available chemicals were used without further purification. Pyrazolyl nitroalkenes were prepared according to the literature procedure.¹ Cinchona derived squaramide catalysts were prepared according to the procedure.² The column chromatography was carried out on a column packed with silica gel 60-120 mesh. ¹H NMR and spectra were recorded in CDCl₃ on a Bruker Avance III (500 MHz) and JEOL (400 MHz) spectrometer. ¹³C NMR spectra were recorded in CDCl₃ on Bruker Avance III (125 MHz) and JEOL (100 MHz) spectrometer. Chemical shifts (δ) are expressed in ppm downfield from internal TMS. HRMS were recorded on micrOTOF-Q II 10356 Mass Spectrometer. Optical rotation was determined with Anton Paar MCP-150 polarimeter at 25°C using sodium D light. HPLC analyses were performed on a Shimadzu LC-20AD using Daicel Chiralpak IA, IB, IC and IE columns.

References:


- 1 P. Rathelot, N. Azas, H. E. Kashef, F. Delmas, C. D. Giorgio, P. T.-. David, J. Maldonado and P. Vanelle, *Eur. J. Med. Chem.*, 2002, **37**, 671-679.
- 2 J. P. Malerich, K. Hagiwara and V. H. Rawal, *J. Am. Chem. Soc.*, 2008, **130**, 14416-14417.

General procedure for the reaction of pyrazolyl nitroalkenes with acetyl acetone




To a stirred solution of (*E*)-4-(2-nitrovinyl)-1,3-diphenyl-1*H*-pyrazole **1** (0.25 mmol) and organocatalyst **I** (1 mol%) in CHCl_3 (1.25 mL) was added acetyl acetone **2a** (0.3 mmol, 1.2 equiv.) at 27°C . The reaction was stirred for 12 h, and progress of the reaction was monitored at regular intervals by thin layer chromatography. The crude reaction mixture was purified by column chromatography on silica gel (mesh 60–120) using *n*-hexane:ethyl acetate (85:15) as the eluents to obtain the pure product **3**.

3-(1-(1,3-diphenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3a)




Light-yellow solid; 87% yield; mp. $95\text{--}96^\circ\text{C}$; $[\alpha]_D^{25} = +170.00$ (c 0.10, CHCl_3); 94% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 13.44$ min (minor) and $t_R = 23.90$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (s, 1H), 7.70 – 7.67 (m, 2H), 7.64 – 7.62 (m, 2H), 7.53 – 7.49 (m, 2H), 7.47 – 7.42 (m, 3H), 7.31 – 7.28 (m, 1H), 4.75 (dd, $J = 12.5, 5.9$ Hz, 1H), 4.59 (dd, $J = 12.4, 4.3$ Hz, 1H), 4.43 – 4.39 (m, 1H), 4.35 (d, $J = 9.4$ Hz, 1H), 2.21 (s, 3H), 2.01 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 202.4, 201.4, 151.7, 139.4, 132.3, 129.4, 129.0, 128.7, 128.4, 126.9, 126.6, 119.1, 115.9, 77.5, 70.0, 32.9, 30.7, 28.7; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_3\text{O}_4$ [$\text{M}+\text{Na}$]⁺ 414.1424; found 414.1449.

3-(1-(3-(2-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3b)



Pale-yellow solid; 76% yield; mp. $71\text{--}73^\circ\text{C}$; $[\alpha]_D^{25} = +130.00$ (c 0.10, CHCl_3); 96% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 8.18$ min (minor) and $t_R = 10.93$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (s, 1H), 7.69 – 7.67 (m, 2H), 7.56 – 7.54 (m, 1H), 7.47 – 7.43 (m, 5H), 7.33 – 7.29 (m, 1H), 4.77 (dd, $J = 12.6, 5.8$ Hz, 1H), 4.60 (dd, $J = 12.6, 4.6$ Hz, 1H), 4.40 (d, $J = 8.7$ Hz, 1H), 3.99 – 3.94 (m, 1H), 2.23 (s, 3H), 2.08 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 202.8, 201.9, 149.9, 139.4, 133.9, 132.5, 131.4, 130.6, 129.9, 129.4, 127.2, 127.0, 126.4, 119.2, 117.3, 76.9, 69.5, 33.2, 30.9, 28.7; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{20}\text{ClN}_3\text{O}_4$ [$\text{M}+\text{H}$]⁺ 426.1215; found 426.1226.


3-(1-(3-(2-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3c)



Pale-yellow solid; 74% yield; mp. $98\text{--}99^\circ\text{C}$; $[\alpha]_D^{25} = +113.33$ (c 0.15, CHCl_3); 92% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 12.11$ min (minor) and $t_R = 18.84$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (s, 1H), 7.73 (dd, $J = 8.0, 0.9$ Hz, 1H), 7.71 – 7.67 (m, 2H), 7.49 – 7.42 (m, 4H), 7.38 – 7.34 (m, 1H), 7.32 – 7.28 (m, 1H), 4.80 (dd, $J = 12.8, 6.0$ Hz, 1H), 4.63 (dd, $J = 12.7, 4.5$ Hz, 1H), 4.41 (d, $J = 8.4$ Hz, 1H), 3.97 – 3.92 (m, 1H), 2.22 (s, 3H), 2.10 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 202.8, 201.9, 151.4, 139.5, 133.5, 133.1, 132.5, 130.8, 129.4, 127.7, 127.0, 126.3,


124.0, 119.2, 117.2, 76.9, 69.4, 33.2, 31.0, 29.0; HRMS (ESI-TOF) m/z: calcd. for $C_{22}H_{20}BrN_3O_4$ [M+Na]⁺ 492.0529; found 492.0509.

3-(1-(3-(3-fluorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3d)




Pale-yellow solid; 74% yield; mp. 48–49°C; $[\alpha]_D^{25} = +166.67$ (c 0.15, CHCl₃); 94% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 12.55$ min (minor) and $t_R = 18.62$ min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.69 – 7.67 (m, 2H), 7.52 – 7.43 (m, 4H), 7.42 – 7.38 (m, 1H), 7.34 – 7.30 (m, 1H), 7.19 – 7.14 (m, 1H), 4.79 – 4.74 (m, 1H), 4.59 (dd, $J = 12.5, 4.0$ Hz, 1H), 4.43 – 4.36 (m, 2H), 2.24 (s, 3H), 2.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.2, 201.2, 163.0 ($J = 245.7$ Hz), 150.4, 139.3, 134.4 (d, $J = 7.9$ Hz), 130.6 (d, $J = 8.4$ Hz), 129.5, 127.1, 126.8, 123.9 (d, $J = 2.6$ Hz), 119.2, 116.0, 115.8, 115.6, 115.4, 77.5, 70.1, 32.8, 30.8, 29.0; HRMS (ESI-TOF) m/z: calcd. for $C_{22}H_{20}FN_3O_4$ [M+Na]⁺ 432.1330; found 432.1293.

3-(1-(3-(3-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3e)




Brown semi-solid; 65% yield; $[\alpha]_D^{25} = +110.00$ (c 0.10, CHCl₃); 94% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 11.93$ min (minor) and $t_R = 16.13$ min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.69 – 7.66 (m, 3H), 7.55 – 7.52 (m, 1H), 7.47 – 7.42 (m, 4H), 7.34 – 7.30 (m, 1H), 4.80 – 4.75 (m, 1H), 4.60 – 4.57 (m, 1H), 4.41 – 4.35 (m, 2H), 2.23 (s, 3H), 2.06 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.2, 201.2, 150.3, 139.3, 134.9, 134.1, 130.2, 129.5, 128.8, 128.6, 127.2, 126.8, 126.3, 119.2, 116.2, 77.5, 70.0, 32.8, 30.8, 29.1; HRMS (ESI-TOF) m/z: calcd. for $C_{22}H_{20}ClN_3O_4$ [M+H]⁺ 426.1215; found 426.1226.

3-(1-(3-(3-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3f)




Light-yellow solid; 74% yield; mp. 43–44°C; $[\alpha]_D^{25} = +106.67$ (c 0.225, CHCl₃); 96% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 9.91$ min (minor) and $t_R = 14.94$ min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.84 – 7.82 (m, 1H), 7.69 – 7.67 (m, 2H), 7.61 – 7.57 (m, 2H), 7.48 – 7.44 (m, 2H), 7.42 – 7.38 (m, 1H), 7.35 – 7.30 (m, 1H), 4.81 – 4.76 (m, 1H), 4.61 – 4.57 (m, 1H), 4.38 – 4.37 (m, 2H), 2.25 (s, 3H), 2.07 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.2, 201.3, 150.2, 139.3, 134.3, 131.8, 131.5, 130.5, 129.5, 127.2, 126.8, 126.7, 123.1, 119.2, 116.1, 77.5, 70.0, 32.8, 30.9, 29.1; HRMS (ESI-TOF) m/z: calcd. for $C_{22}H_{20}BrN_3O_4$ [M+H]⁺ 470.0710; found 470.0728.

3-(1-(3-(4-fluorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3g)




Light-brown semi-solid; 70% yield; $[\alpha]_D^{25} = +130.00$ (c 0.10, CHCl₃); 90% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 9.19$ min (minor) and $t_R = 15.43$ min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.68 – 7.61 (m, 4H), 7.48 – 7.44 (m, 2H), 7.33 – 7.30 (m, 1H), 7.24 – 7.19 (m, 2H), 4.76 – 4.72 (m, 1H), 4.59 – 4.55 (m, 1H), 4.39 – 4.33 (m, 2H), 2.24 (s, 3H), 2.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.2, 201.3, 163.0 (d, $J = 247.2$ Hz), 150.9, 139.4, 130.3 (d, $J = 8.4$ Hz), 129.5, 128.4, 127.1, 126.6, 119.2, 116.21, 116.0, 115.9, 77.6, 70.1, 32.9, 30.8, 29.0; HRMS (ESI-TOF) m/z: calcd. for $C_{22}H_{20}FN_3O_4$ [M+H]⁺ 410.1511; found 410.1497.

3-(1-(3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3h)




Light-brown solid; 62% yield; mp. 44–45°C; $[\alpha]_D^{25} = +100.00$ (c 0.10, CHCl₃); 95% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 9.73 min (minor) and t_R = 19.60 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.68 – 7.66 (m, 2H), 7.61 – 7.59 (m, 2H), 7.51 – 7.48 (m, 2H), 7.46 – 7.44 (m, 2H), 7.34 – 7.30 (m, 1H), 4.76 – 4.72 (m, 1H), 4.59 – 4.55 (m, 1H), 4.40 – 4.35 (m, 2H), 2.24 (s, 3H), 2.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.2, 201.2, 150.6, 139.3, 134.9, 130.8, 129.7, 129.5, 129.3, 127.1, 126.8, 119.2, 116.0, 77.6, 70.1, 32.9, 30.8, 29.1; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀ClN₃O₄ [M+Na]⁺ 448.1035 found 448.1012.

3-(1-(3-(4-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3i)




Light-yellow solid; 60% yield; mp. 51–52°C; $[\alpha]_D^{25} = +120.00$ (c 0.10, CHCl₃); 94% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 14.32 min (minor) and t_R = 31.56 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.68 – 7.65 (m, 4H), 7.55 – 7.52 (m, 2H), 7.49 – 7.44 (m, 2H), 7.34 – 7.30 (m, 1H), 4.76 – 4.72 (m, 1H), 4.59 – 4.55 (m, 1H), 4.40 – 4.36 (m, 2H), 2.25 (s, 3H), 2.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.2, 201.2, 150.6, 139.3, 132.2, 131.3, 130.0, 129.5, 127.2, 126.8, 123.1, 119.2, 115.9, 77.6, 70.1, 32.9, 30.9, 29.1; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀BrN₃O₄ [M+H]⁺ 470.0710; found 470.0684.

3-(1-(3-(2,4-dichlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3j)




Pale-yellow solid; 71% yield; mp. 56–57°C; $[\alpha]_D^{25} = +95.00$ (c 0.20, CHCl₃); 97% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 10.02 min (minor) and t_R = 14.01 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (s, 1H), 7.67 (d, *J* = 7.8 Hz, 2H), 7.58 (d, *J* = 1.4 Hz, 1H), 7.48 – 7.40 (m, 4H), 7.34 – 7.30 (m, 1H), 4.76 (dd, *J* = 12.7, 5.9 Hz, 1H), 4.59 (dd, *J* = 12.7, 4.5 Hz, 1H), 4.41 (d, *J* = 8.8 Hz, 1H), 3.95 – 3.91 (m, 1H), 2.24 (s, 3H), 2.10 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.5, 201.6, 148.9, 139.3, 136.0, 134.6, 133.30, 129.9, 129.7, 129.5, 127.6, 127.2, 126.5, 119.2, 117.4, 77.0, 69.5, 33.1, 31.0, 29.1; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₁₉Cl₂N₃O₄ [M+Na]⁺ 482.0645; found 482.0607.

3-(2-nitro-1-(1-phenyl-3-(*p*-tolyl)-1*H*-pyrazol-4-yl)ethyl)pentane-2,4-dione (3k)




Light-yellow solid; 83% yield; mp. 53–54°C; $[\alpha]_D^{25} = +155.00$ (c 0.20, CHCl₃); 92% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 12.93 min (minor) and t_R = 29.67 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.69 – 7.67 (m, 2H), 7.52 – 7.50 (m, 2H), 7.46 – 7.42 (m, 2H), 7.33 – 7.27 (m, 3H), 4.75 (dd, *J* = 12.4, 5.5 Hz, 1H), 4.59 (dd, *J* = 12.4, 4.2 Hz, 1H), 4.40 – 4.35 (m, 2H), 2.43 (s, 3H), 2.22 (s, 3H), 2.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.5, 201.6, 151.8, 139.5, 138.7, 129.7, 129.4, 129.4, 128.3, 128.3, 128.3, 126.9, 126.6, 119.1, 119.1, 115.8, 77.5, 70.1, 33.0, 30.8, 28.6, 21.4; HRMS (ESI-TOF) m/z: calcd. for C₂₃H₂₃N₃O₄ [M+Na]⁺ 428.1581; found 428.1580.



3-(1-(3-(2-methoxyphenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl) pentane-2,4-dione (3l)


Light brown solid; 68% yield; mp. 43–45°C; $[\alpha]_D^{25} = +120.00$ (c 0.15, CHCl₃); 95% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 8.33 min (minor) and t_R = 12.99 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.69 – 7.66 (m, 2H), 7.48 – 7.41 (m, 4H), 7.29 – 7.26 (m, 1H), 7.11 – 7.04 (m, 2H), 4.71 (dd, J = 12.1, 5.0 Hz, 1H), 4.60 (dd, J = 12.1, 5.3 Hz, 1H), 4.36 (d, J = 9.6 Hz, 1H), 4.12 – 4.07 (m, 1H), 3.85 (s, 3H), 2.19 (s, 3H), 2.00 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 203.0, 202.3, 156.9, 149.7, 139.5, 132.0, 130.7, 129.3, 126.6, 126.4, 121.3, 121.1, 119.0, 117.4, 111.1, 77.1, 69.9, 55.4, 33.5, 30.5, 27.9; HRMS (ESI-TOF) m/z: calcd. for C₂₃H₂₃N₃O₅ [M+Na]⁺ 444.1530; found 444.1493.

3-(1-(3-(4-methoxyphenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl) pentane-2,4-dione (3m)




Brown solid; 75% yield; mp. 41–42°C; $[\alpha]_D^{25} = +140.00$ (c 0.20, CHCl₃); 90% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 19.04 min (minor) and t_R = 38.82 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.69 – 7.67 (m, 2H), 7.57 – 7.55 (m, 2H), 7.46 – 7.42 (m, 2H), 7.31 – 7.26 (m, 1H), 7.06 – 7.02 (m, 2H), 4.74 (dd, J = 12.4, 5.7 Hz, 1H), 4.59 (dd, J = 12.4, 4.2 Hz, 1H), 4.42 – 4.34 (m, 2H), 3.87 (s, 3H), 2.22 (s, 3H), 2.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.4, 201.5, 160.0, 151.6, 139.5, 129.7, 129.4, 126.8, 126.6, 124.7, 119.1, 115.8, 114.5, 77.5, 70.1, 55.3, 33.0, 30.8, 28.7; HRMS (ESI-TOF) m/z: calcd. for C₂₃H₂₃N₃O₅ [M+H]⁺ 422.1710; found 422.1691.

3-(2-nitro-1-(3-(4-nitrophenyl)-1-phenyl-1*H*-pyrazol-4-yl)ethyl)pentane-2,4-dione (3n)




Yellow solid; 70% yield; mp. 92–94°C; $[\alpha]_D^{25} = +20.00$ (c 0.10, CHCl₃); 95% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 31.25 min (minor) and t_R = 45.95 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 8.40 – 8.38 (m, 2H), 7.93 – 7.89 (m, 3H), 7.70 – 7.68 (m, 2H), 7.51 – 7.47 (m, 2H), 7.38 – 7.34 (m, 1H), 4.75 (dd, J = 12.6, 6.1 Hz, 1H), 4.58 (dd, J = 12.6, 4.1 Hz, 1H), 4.48 – 4.39 (m, 2H), 2.29 (s, 3H), 2.09 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 201.7, 200.8, 149.4, 147.8, 139.1, 138.9, 129.6, 129.1, 127.6, 127.0, 124.2, 119.3, 116.7, 77.7, 70.1, 32.8, 30.9, 29.8; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀N₄O₆ [M+Na]⁺ 459.1275; found 459.1220.

3-(1-(3-(naphthalen-2-yl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)pentane-2,4-dione (3o)



Light-brown solid; 60% yield; mp. 53–54°C; $[\alpha]_D^{25} = +140.00$ (c 0.10, CHCl₃); 93% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 10.49 min (minor) and t_R = 16.23 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, J = 0.8 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.97 – 7.91 (m, 2H), 7.90 (s, 1H), 7.77 (dd, J = 8.4, 1.7 Hz, 1H), 7.73 – 7.71 (m, 2H), 7.57 – 7.55 (m, 2H), 7.49 – 7.45 (m, 2H), 7.34 – 7.30 (m, 1H), 4.80 (dd, J = 12.4, 6.1 Hz, 1H), 4.64 (dd, J = 12.4, 4.6 Hz, 1H), 4.55 – 4.50 (m, 1H), 4.38 (d, J = 9.2 Hz, 1H), 2.21 (s, 3H), 2.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.4, 201.6, 151.6, 139.5, 133.4, 133.2, 129.8, 129.5, 128.9, 128.4, 127.8, 127.6, 127.0, 126.9, 126.7, 126.6, 126.0, 119.2, 116.2, 77.5, 70.0, 33.0, 30.9, 28.8; HRMS (ESI-TOF) m/z: calcd. for C₂₆H₂₃N₃O₄ [M+Na]⁺ 464.1581; found 464.1566.


3,5-dimethyl-4-(2-nitro-1-(1-phenyl-3-(thiophen-2-yl)-1*H*-pyrazol-4-yl)ethyl)pentane-2,4-dione (3p)



Brown semi-solid; 69% yield; $[\alpha]_D^{25} = +66.67$ (c 0.15, CHCl₃); 97% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 9.97 min (minor) and t_R = 12.21 min (major)]; ¹H


NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.69 – 7.66 (m, 2H), 7.47 – 7.42 (m, 4H), 7.33 – 7.29 (m, 1H), 7.18 (dd, *J* = 5.1, 3.6 Hz, 1H), 4.80 (dd, *J* = 12.4, 5.9 Hz, 1H), 4.68 (dd, *J* = 12.4, 4.7 Hz, 1H), 4.59 – 4.54 (m, 1H), 4.44 (d, *J* = 9.4 Hz, 1H), 2.27 (s, 3H), 2.06 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.5, 201.5, 145.5, 139.2, 133.7, 129.5, 127.9, 127.2, 127.1, 126.4, 125.9, 119.2, 115.6, 77.3, 70.0, 33.0, 30.8, 28.4; HRMS (ESI-TOF) m/z: calcd. for C₂₀H₁₉N₃O₄S [M+Na]⁺ 420.0988; found 420.0985.

3-(2-nitro-1-(1-(4-nitrophenyl)-3-phenyl-1*H*-pyrazol-4-yl)ethyl)pentane-2,4-dione (3q)




Yellow brown solid; 55% yield; mp. 72–74 °C; [α]_D²⁵ = +60.00 (c 0.10, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.36 – 8.33 (m, 2H), 7.98 (s, 1H), 7.90 – 7.88 (m, 2H), 7.64 – 7.62 (m, 2H), 7.58 – 7.51 (m, 3H), 4.80 (dd, *J* = 12.6, 5.9 Hz, 1H), 4.60 (dd, *J* = 12.6, 4.4 Hz, 1H), 4.43 – 4.33 (m, 2H), 2.23 (s, 3H), 2.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 202.3, 201.5, 153.5, 145.7, 143.6, 131.5, 129.4, 129.2, 128.4, 127.1, 125.4, 118.7, 117.9, 77.2, 69.7, 32.8, 30.8, 28.8; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀N₄O₆ [M+Na]⁺ 437.1456; found 437.1433.

General procedure for the synthesis of bis-pyrazole derivatives 4




To a stirred solution of compound 3 (0.1 mmol) in 2 mL ethanol was added phenyl hydrazine 7 (0.11 mmol, 1.2 equiv.) and 20 mol% glacial acetic acid. The reaction mixture was refluxed at 90 °C for 3h, after which the solvent was reduced under pressure, and the crude reaction mixture was purified by column chromatography on silica gel (mesh 60–120) using *n*-hexane:ethyl acetate (85:15) as the eluents to obtain 4 as the pure product.

4-(1-(1,3-diphenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4a)



Reddish brown semi-solid, 81% yield, [α]_D²⁵ = +45.00 (c 0.2, CHCl₃); 99% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 7.97 min (minor) and t_R = 13.00 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, *J* = 0.4 Hz, 1H), 7.73 – 7.70 (m, 2H), 7.58 – 7.55 (m, 2H), 7.48 – 7.42 (m, 7H), 7.38 – 7.36 (m, 1H), 7.32 – 7.29 (m, 3H), 5.07 (dd, *J* = 9.0, 7.4 Hz, 1H), 4.90 (dd, *J* = 12.4, 7.1 Hz, 1H), 4.78 (dd, *J* = 12.4, 9.4 Hz, 1H), 2.23 (s, 3H), 2.09 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.8, 146.9, 139.7, 139.3, 137.4, 133.0, 129.5, 129.1, 128.6, 128.5, 128.2, 127.8, 126.7, 125.8, 125.2, 119.0, 118.6, 113.7, 77.4, 31.2, 13.2, 10.9; HRMS (ESI-TOF) m/z: calcd. for C₂₈H₂₅N₅O₂ [M+H]⁺ 464.2081; found 464.2065.


4-(1-(3-(2-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4b)



Reddish brown semi-solid; 57% yield; [α]_D²⁵ = +76.00 (c = 0.5, CHCl₃); 97% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 7.82 min (minor) and t_R = 13.61 min (major)]; ¹H


NMR (400 MHz, CDCl₃) δ 7.89 (d, *J* = 0.8 Hz, 1H), 7.73 – 7.71 (m, 2H), 7.49 – 7.44 (m, 4H), 7.42 – 7.40 (m, 2H), 7.36 – 7.29 (m, 4H), 7.24 – 7.21 (m, 2H), 4.96 – 4.91 (m, 2H), 4.82 (dd, *J* = 14.4, 11.8 Hz, 1H), 2.07 (s, 3H), 1.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.2, 146.8, 139.7, 139.4, 137.5, 134.1, 132.3, 131.6, 130.1, 129.5, 129.4, 129.0, 127.7, 126.8, 126.7, 125.1, 124.2, 120.5, 119.0, 113.5, 77.4, 31.0, 12.8, 10.4; HRMS (ESI-TOF) m/z: calcd. for C₂₈H₂₄ClN₅O₂ [M+H]⁺ 498.1691; found 498.1744.

4-(1-(3-(2-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4c)




Reddish brown semi-solid; 60% yield; [α]_D²⁵ = +110.00 (c = 0.5, CHCl₃); 93% ee, HPLC [Chiralpak IA, hexane/i-PrOH 85:15, 1ml/min, 254 nm, t_R = 10.25 min (minor) and t_R = 18.14 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.73 – 7.71 (m, 2H), 7.64 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.48 – 7.43 (m, 3H), 7.42 – 7.40 (m, 2H), 7.36 – 7.32 (m, 2H), 7.30 – 7.27 (m, 1H), 7.23 – 7.21 (m, 2H), 7.19 – 7.17 (m, 1H), 4.98 – 4.87 (m, 2H), 4.82 (dd, *J* = 9.7, 7.3 Hz, 1H), 2.07 (s, 3H), 1.90 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.6, 146.8, 139.6, 139.4, 137.5, 134.3, 132.5, 131.6, 130.2, 129.5, 129.0, 127.6, 127.3, 126.7, 125.1, 124.1, 124.0, 120.2, 119.0, 113.5, 77.1, 31.0, 12.8, 10.4; HRMS (ESI-TOF) m/z: calcd. for C₂₈H₂₄BrN₅O₂ [M+H]⁺ 542.1186; found 542.1187.

4-(1-(3-(3-fluorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4d)




Reddish brown semi-solid; 71% yield; [α]_D²⁵ = +74.00 (c = 0.5, CHCl₃); 97% ee, HPLC [Chiralpak IA, hexane/i-PrOH 85:15, 1ml/min, 254 nm, t_R = 7.55 min (minor) and t_R = 10.32 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J* = 0.6 Hz, 1H), 7.73 – 7.70 (m, 2H), 7.50 – 7.48 (m, 2H), 7.45 – 7.43 (m, 2H), 7.39 – 7.27 (m, 7H), 7.11 – 7.06 (m, 1H), 5.06 – 5.02 (m, 1H), 4.93 (dd, *J* = 12.3, 7.6 Hz, 1H), 4.79 (dd, *J* = 12.3, 8.9 Hz, 1H), 2.22 (s, 3H), 2.12 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.7 (d, *J* = 245.4 Hz), 150.6, 146.8, 139.6, 139.3, 137.4, 135.1 (d, *J* = 7.9 Hz), 130.2 (d, *J* = 8.4 Hz), 129.6, 129.1, 127.9, 127.0, 125.9, 125.2, 123.8, 119.1, 118.6, 115.4, 115.2, 113.6, 77.6, 31.3, 13.2, 10.9; HRMS (ESI-TOF) m/z: calcd. for C₂₈H₂₄FN₅O₂ [M+Na]⁺ 504.1806; found 504.1741.

4-(1-(3-(3-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4e)



Reddish brown semi-solid; 67% yield; [α]_D²⁵ = +34.00 (c = 0.5, CHCl₃); 95% ee, HPLC [Chiralpak IA, hexane/i-PrOH 85:15, 1ml/min, 254 nm, t_R = 9.17 min (minor) and t_R = 12.68 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 0.7 Hz, 1H), 7.73 – 7.70 (m, 2H), 7.51 – 7.49 (m, 2H), 7.48 – 7.46 (m, 3H), 7.44 – 7.42 (m, 2H), 7.39 – 7.38 (m, 1H), 7.35 – 7.34 (m, 2H), 7.31 – 7.29 (m, 2H), 5.04 – 5.00 (m, 1H), 4.95 (dd, *J* = 12.1, 7.7 Hz, 1H), 4.78 (dd, *J* = 12.1, 8.3 Hz, 1H), 2.19 (s, 3H), 2.12 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.5, 146.9, 139.6, 139.3, 137.4, 134.8, 134.4, 129.8, 129.6, 129.1, 128.5, 128.3, 127.9, 127.0, 126.3, 125.7, 125.3, 119.2, 118.7, 113.6, 77.7, 31.3, 13.2, 10.9; HRMS (ESI-TOF) m/z: calcd. for C₂₈H₂₄ClN₅O₂ [M+H]⁺ 498.1691; found 498.1746.


4-(1-(3-(2-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4f)



Reddish brown semi-solid; 70% yield; [α]_D²⁵ = +72.00 (c = 0.5, CHCl₃); 98% ee, HPLC [Chiralpak IA, hexane/i-PrOH 85:15, 1ml/min, 254 nm, t_R = 7.84 min (minor) and t_R = 10.44 min


(major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, $J = 0.5$ Hz, 1H), 7.73 – 7.71 (m, 2H), 7.66 – 7.65 (m, 1H), 7.51 – 7.46 (m, 5H), 7.45 – 7.43 (m, 2H), 7.39–7.37 (m, 1H), 7.33 – 7.30 (m, 3H), 5.04 – 5.00 (m, 1H), 4.95 (dd, $J = 12.0, 7.8$ Hz, 1H), 4.78 (dd, $J = 12.0, 8.2$ Hz, 1H), 2.19 (s, 3H), 2.13 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.4, 146.8, 139.5, 139.3, 137.4, 135.0, 131.4, 131.2, 130.1, 129.6, 129.1, 127.9, 127.0, 126.8, 125.7, 125.3, 122.5, 119.1, 118.7, 113.5, 77.7, 31.3, 13.2, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{24}\text{BrN}_5\text{O}_2$ [M+H] $^+$ 542.1186; found 542.1100.

4-(1-(3-(4-fluorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4g)




Reddish brown semi-solid; 76% yield; $[\alpha]_D^{25} = +52.00$ ($c = 0.5$, CHCl_3); 91% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, $t_R = 9.23$ min (minor) and $t_R = 16.36$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.85 (d, $J = 0.9$ Hz, 1H), 7.72 – 7.69 (m, 2H), 7.54 – 7.49 (m, 3H), 7.47 (d, $J = 1.2$ Hz, 1H), 7.45 – 7.43 (m, 2H), 7.39 – 7.37 (m, 1H), 7.34 – 7.31 (m, 1H), 7.31 – 7.28 (m, 2H), 7.14 – 7.10 (m, 2H), 5.03 – 4.99 (m, 1H), 4.91 (dd, $J = 12.3, 7.4$ Hz, 1H), 4.81 – 4.76 (m, 1H), 2.21 (s, 3H), 2.09 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.9, 146.8, 139.6, 139.3, 137.3, 130.1, 130.0, 129.5, 129.1, 127.9, 126.8, 125.7, 125.2, 119.1, 118.5, 115.7, 115.5, 113.7, 77.5, 31.2, 13.2, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{24}\text{FN}_5\text{O}_2$ [M+H] $^+$ 482.1987; found 482.1984.

4-(1-(3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4h)




Reddish brown semi-solid, 65% yield, $[\alpha]_D^{25} = +48.00$ ($c = 0.5$, CHCl_3); 96% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1 mL/min, 254 nm; $t_R = 8.71$ min (minor) and $t_R = 15.59$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.85 (s, 1H), 7.71 – 7.69 (m, 2H), 7.51 – 7.44 (m, 7H), 7.41 – 7.3 (m, 3H), 7.30 – 7.28 (m, 2H), 5.04 – 5.00 (m, 1H), 4.92 (dd, $J = 12.4, 7.4$ Hz, 1H), 4.79 (d, $J = 12.3, 9$ Hz, 1H), 2.21 (s, 3H), 2.11 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.6, 146.8, 139.6, 139.3, 137.4, 134.5, 131.5, 129.6, 129.5, 129.1, 128.8, 127.9, 126.9, 125.9, 125.2, 119.1, 118.6, 113.6, 77.5, 31.3, 13.2, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{24}\text{ClN}_5\text{O}_2$ [M+H] $^+$ 498.1691; found 498.1607.

4-(1-(3-(4-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4i)



Reddish brown semi-solid, 79% yield, $[\alpha]_D^{25} = +32.00$ ($c = 0.5$, CHCl_3); 86% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1 mL/min, 254 nm; $t_R = 9.24$ min (minor) and $t_R = 17.22$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.85 (d, $J = 0.7$ Hz, 1H), 7.72 – 7.69 (m, 2H), 7.56 – 7.54 (m, 2H), 7.49 – 7.45 (m, 4H), 7.44 – 7.42 (m, 2H), 7.40 – 7.32 (m, 2H), 7.30 – 7.27 (m, 2H), 5.04 – 5.00 (m, 1H), 4.92 (dd, $J = 12.3, 7.4$ Hz, 1H), 4.78 (dd, $J = 12.3, 8.9$ Hz, 1H), 2.20 (s, 3H), 2.11 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.6, 146.8, 139.6, 139.2, 137.4, 132.0, 131.7, 129.8, 129.6, 129.1, 127.9, 126.9, 125.9, 125.3, 122.7, 119.1, 118.6, 113.6, 77.5, 31.3, 13.2, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{24}\text{BrN}_5\text{O}_2$ [M+Na] $^+$ 564.1006; found 564.1010.


4-(1-(3-(2,4-dichlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4j)



Reddish brown semi-solid, 60% yield, $[\alpha]_D^{25} = +46.00$ ($c = 0.5$, CHCl_3); 94% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1 mL/min, 254 nm; $t_R = 10.08$ min (minor) and $t_R = 20.70$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.90 (s, 1H), 7.72 – 7.70 (m, 2H), 7.48 – 7.46 (m, 3H), 7.44 – 7.42 (m,


2H), 7.38 – 7.33 (m, 2H), 7.24 – 7.18 (m, 3H), 7.13 (d, J = 8.2 Hz, 1H), 4.99 – 4.89 (m, 2H), 4.81 (dd, J = 11.0, 8.2 Hz, 1H), 2.04 (s, 3H), 1.97 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.1, 146.7, 139.5, 139.2, 137.5, 135.3, 134.8, 132.3, 131.0, 129.6, 129.1, 129.0, 127.8, 127.1, 127.0, 125.1, 124.2, 120.7, 119.1, 113.4, 77.2, 31.0, 12.9, 10.5; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{23}\text{Cl}_2\text{N}_5\text{O}_2$ [$\text{M}+\text{H}]^+$ 532.1302; found 532.1323.

3,5-dimethyl-4-(2-nitro-1-(1-phenyl-3-(*p*-tolyl)-1*H*-pyrazol-4-yl)ethyl)-1-phenyl-1*H*-pyrazole (4k)




Reddish brown semi-solid; 64% yield; $[\alpha]_D^{25} = +30.00$ ($c = 0.5$, CHCl_3); 84% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 7.78 min (minor) and t_R = 12.72 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 0.8 Hz, 1H), 7.72 – 7.69 (m, 2H), 7.49 – 7.43 (m, 7H), 7.39 – 7.35 (m, 1H), 7.33 – 7.32 (m, 1H), 7.31 – 7.30 (m, 1H), 7.25 – 7.23 (m, 2H), 5.10 – 5.05 (m, 1H), 4.89 (dd, J = 12.4, 6.9 Hz, 1H), 4.77 (dd, J = 12.4, 9.6 Hz, 1H), 2.39 (s, 3H), 2.25 (s, 3H), 2.13 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.7, 146.9, 139.7, 139.4, 138.3, 137.5, 130.1, 129.5, 129.4, 129.1, 128.0, 127.8, 126.6, 126.0, 125.2, 119.0, 118.4, 113.8, 77.2, 31.3, 21.3, 13.3, 11.1; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{29}\text{H}_{27}\text{N}_5\text{O}_2$ [$\text{M}+\text{H}]^+$ 478.2238; found 478.2193.

4-(1-(3-(2-methoxyphenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4l)




Reddish brown semi-solid; 68% yield; $[\alpha]_D^{25} = +28.00$ ($c = 0.5$, CHCl_3); 96% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 8.13 min (minor) and t_R = 14.92 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, J = 0.7 Hz, 1H), 7.71 – 7.69 (m, 2H), 7.46 – 7.41 (m, 5H), 7.39 – 7.35 (m, 3H), 7.29 – 7.26 (m, 1H), 7.28 – 7.27 (m, 1H), 7.03 – 6.99 (m, 1H), 6.98 (d, J = 8.3 Hz, 1H), 5.08 – 5.04 (m, 1H), 4.79 – 4.75 (m, 2H), 3.88 (s, 3H), 2.19 (s, 3H), 2.04 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.2, 149.6, 147.0, 139.8, 139.5, 137.4, 131.3, 130.3, 129.4, 129.0, 127.6, 126.5, 125.1, 125.0, 122.0, 120.9, 120.7, 118.9, 114.0, 110.6, 77.23, 55.5, 31.4, 13.1, 10.7; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{29}\text{H}_{27}\text{N}_5\text{O}_3$ [$\text{M}+\text{H}]^+$ 494.2187; found 494.2286.

4-(1-(3-(4-methoxyphenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethyl-1-phenyl-1*H*-pyrazole (4m)



Reddish brown semi-solid; 56% yield; $[\alpha]_D^{25} = +22.50$ ($c = 0.4$, CHCl_3); 92% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 13.16 min (minor) and t_R = 24.11 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 0.8 Hz, 1H), 7.71 – 7.69 (m, 2H), 7.51 – 7.49 (m, 2H), 7.47 – 7.43 (m, 4H), 7.39 – 7.34 (m, 1H), 7.33 – 7.29 (m, 3H), 6.97 – 6.95 (m, 2H), 5.07 – 5.03 (m, 1H), 4.90 (dd, J = 12.4, 7.0 Hz, 1H), 4.78 (dd, J = 12.4, 9.5 Hz, 1H), 3.84 (s, 3H), 2.24 (s, 3H), 2.13 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.8, 151.6, 146.9, 139.8, 139.4, 137.5, 129.5, 129.4, 129.1, 127.8, 126.6, 125.8, 125.4, 125.2, 119.0, 118.4, 114.1, 113.9, 77.4, 55.3, 31.4, 13.3, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{29}\text{H}_{27}\text{N}_5\text{O}_3$ [$\text{M}+\text{H}]^+$ 494.2187; found 494.2241.


3,5-dimethyl-4-(2-nitro-1-(3-(4-nitrophenyl)-1-phenyl-1*H*-pyrazol-4-yl)ethyl)-1-phenyl-1*H*-pyrazole (4n)



Reddish brown semi-solid; 63% yield; $[\alpha]_D^{25} = +7.50$ ($c = 0.4$, CHCl_3); 95% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 13.60 min (minor) and t_R = 24.69


min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 8.29 – 8.26 (m, 2H), 7.95 (s, 1H), 7.78 – 7.76 (m, 2H), 7.74 – 7.72 (m, 2H), 7.52 – 7.48 (m, 2H), 7.45 – 7.43 (m, 2H), 7.40 – 7.35 (m, 2H), 7.27 – 7.25 (m, 2H), 5.10 – 5.06 (m, 1H), 4.95 (dd, J = 12.4, 7.8 Hz, 1H), 4.81 (dd, J = 12.4, 8.3 Hz, 1H), 2.20 (s, 3H), 2.14 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.3, 147.5, 146.7, 139.6, 139.4, 139.1, 137.3, 129.7, 129.2, 128.8, 128.0, 127.4, 126.3, 125.1, 123.7, 119.2, 113.4, 77.7, 31.4, 13.2, 11.1; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{24}\text{N}_6\text{O}_4$ [M+Na] $^+$ 531.1751; found 531.1744.

3,5-dimethyl-4-(1-(3-(naphthalen-2-yl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1*H*-pyrazole (4o)




Reddish brown semi-solid; 75% yield; $[\alpha]_D^{25} = +4.00$ ($c = 0.5$, CHCl_3); 98% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 10.07 min (minor) and t_R = 14.57 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 8.00 (s, 1H), 7.91 – 7.84 (m, 5H), 7.76 – 7.72 (m, 3H), 7.53 – 7.52 (m, 1H), 7.49 – 7.47 (m, 2H), 7.39 – 7.38 (m, 2H), 7.36 – 7.33 (m, 2H), 7.17 – 7.15 (m, 2H), 5.17 (dd, J = 8.6, 7.6 Hz, 1H), 4.96 (dd, J = 12.4, 7.2 Hz, 1H), 4.80 (dd, J = 12.4, 9.2 Hz, 1H), 2.24 (s, 3H), 2.08 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.7, 146.9, 139.8, 139.3, 137.5, 133.2, 133.1, 130.5, 129.6, 129.0, 128.3, 128.2, 127.8, 127.3, 126.8, 126.5, 126.4, 126.0, 125.9, 125.2, 119.1, 118.9, 113.8, 77.6, 31.5, 13.3, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{32}\text{H}_{27}\text{N}_5\text{O}_2$ [M+H] $^+$ 514.2238; found 514.2297.

3,5-dimethyl-4-(2-nitro-1-(1-phenyl-3-(thiophen-2-yl)-1*H*-pyrazol-4-yl)ethyl)-1-phenyl-1*H*-pyrazole (4p)




Reddish brown semi-solid; 66% yield; $[\alpha]_D^{25} = +18.00$ ($c = 0.5$, CHCl_3); 95% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 8.86 min (minor) and t_R = 11.87 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, J = 0.8 Hz, 1H), 7.71 – 7.68 (m, 2H), 7.48 – 7.44 (m, 5H), 7.38 – 7.37 (m, 2H), 7.35 – 7.33 (m, 2H), 7.33 – 7.29 (m, 1H), 7.12 (dd, J = 5.1, 3.6 Hz, 1H), 5.14 (dd, J = 9.6, 6.7 Hz, 1H), 4.98 (dd, J = 12.5, 6.7 Hz, 1H), 4.85 (dd, J = 12.5, 9.6 Hz, 1H), 2.33 (s, 3H), 2.20 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 146.8, 145.6, 139.5, 139.3, 137.6, 134.5, 129.5, 129.1, 127.8, 127.7, 126.9, 126.7, 126.2, 125.7, 125.3, 119.1, 118.3, 113.5, 77.1, 31.6, 13.4, 11.1; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{26}\text{H}_{23}\text{N}_5\text{O}_2\text{S}$ [M+Na] $^+$ 492.1465; found 492.1410.

3,5-dimethyl-4-(2-nitro-1-(1-(4-nitrophenyl)-3-phenyl-1*H*-pyrazol-4-yl)ethyl)-1-phenyl-1*H*-pyrazole (4q)




Reddish brown semi-solid; 52% yield; $[\alpha]_D^{25} = +75.00$ ($c = 0.2$, CHCl_3); 74% ee, HPLC [Chiralpak IA, hexane/*i*-PrOH 85:15, 1ml/min, 254 nm, t_R = 20.40 min (minor) and t_R = 23.98 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 8.36 – 8.34 (m, 2H), 7.94 (d, J = 0.9 Hz, 1H), 7.92 – 7.90 (m, 2H), 7.56 – 7.53 (m, 2H), 7.46 – 7.42 (m, 5H), 7.39 – 7.38 (m, 1H), 7.29 – 7.27 (m, 2H), 5.09 – 5.04 (m, 1H), 4.92 (dd, J = 12.5, 7.5 Hz, 1H), 4.78 (dd, J = 12.5, 8.9 Hz, 1H), 2.22 (s, 3H), 2.08 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.7, 146.7, 145.5, 143.9, 139.3, 137.5, 132.2, 129.1, 129.0, 128.8, 128.2, 127.9, 125.8, 125.5, 125.2, 122.0, 120.8, 118.4, 113.3, 113.2, 77.2, 31.3, 13.3, 10.9; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{28}\text{H}_{24}\text{N}_6\text{O}_4$ [M+H] $^+$ 509.1932; found 509.1919.

General procedure for the synthesis of 5




To a stirred solution of compound **3** (0.1 mmol) in 2 mL ethanol was added hydrazine hydrate (0.15 mmol, 1.5 equiv.) and 20 mol% glacial acetic acid. The reaction mixture was run for 12 h at 28 °C, after which the solvent was reduced under pressure, and the crude reaction mixture was purified by column chromatography on silica gel (mesh 60–120) using *n*-hexane:ethyl acetate (75:25) as the eluents to procure the final product **5**.

4-(1-(3,5-dimethyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-1,3-diphenyl-1*H*-pyrazole (5a)




Off-white solid; 66% yield; mp. 78–79°C; $[\alpha]_D^{25} = +40.00$ ($c = 0.15$, CHCl_3); 87% *ee*; HPLC [Chiralpak IE, hexane/*i*-PrOH 85:15, 1 mL/min, 254 nm, $t_R = 13.89$ min (minor) and $t_R = 14.86$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (s, 1H), 7.70 – 7.68 (m, 2H), 7.58 – 7.56 (m, 2H), 7.46 – 7.37 (m, 5H), 7.31 – 7.27 (m, 1H), 6.46 (s, 1H), 5.02 (dd, $J = 9.4, 7.2$ Hz, 1H), 4.81 (dd, $J = 12.4, 7.0$ Hz, 1H), 4.70 (dd, $J = 12.3, 9.6$ Hz, 1H), 2.15 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.6, 142.4, 139.6, 132.8, 129.5, 128.7, 128.5, 128.1, 126.7, 126.1, 119.0, 118.5, 111.7, 77.4, 30.8, 11.5; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_5\text{O}_2$ [$\text{M}+\text{Na}$]⁺ 410.1587; found 410.1525.

3-(2-chlorophenyl)-4-(1-(3,5-dimethyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1*H*-pyrazole (5b)




Off-white solid; 72% yield; mp. 87–89°C; $[\alpha]_D^{25} = +75.00$ ($c 0.2$, CHCl_3); 98% *ee*; HPLC [Chiralpak IA, hexane/*i*-PrOH, 80:20, 1 mL/min, 254 nm, $t_R = 12.84$ min (minor) and $t_R = 25.43$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.80 (s, 1H), 7.70 – 7.68 (m, 2H), 7.47 – 7.43 (m, 3H), 7.34 – 7.28 (m, 2H), 7.26 – 7.20 (m, 2H), 7.13 (s, 1H), 4.86 (dd, $J = 9.8, 6.7$ Hz, 1H), 4.81 – 4.70 (m, 2H), 2.00 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.9, 142.2, 139.6, 134.0, 132.1, 131.6, 130.2, 129.5, 129.5, 126.8, 126.8, 124.6, 120.4, 119.0, 111.6, 77.2, 30.5, 11.1; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{20}\text{ClN}_5\text{O}_2$ [$\text{M}+\text{H}$]⁺ 422.1378; found 422.1397.

3-(2-bromophenyl)-4-(1-(3,5-dimethyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1*H*-pyrazole (5c)




Off-white solid; 73% yield; mp. 96–97°C; $[\alpha]_D^{25} = +70.00$ ($c 0.1$, CHCl_3); 90% *ee*; HPLC [Chiralpak IA, hexane/*i*-PrOH, 80:20, 1 mL/min, 254 nm, $t_R = 13.28$ min (minor) and $t_R = 22.47$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.81 (s, 1H), 7.71 – 7.69 (m, 2H), 7.65 (dd, $J = 7.9, 1.3$ Hz, 1H), 7.48 – 7.44 (m, 2H), 7.33 – 7.29 (m, 2H), 7.25 – 7.23 (m, 1H), 7.18 (dd, $J = 7.3, 1.9$ Hz, 1H), 4.87 – 4.72 (m, 3H), 4.34 (s, 1H), 2.00 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.4, 142.5, 139.6, 134.16, 132.72, 131.67, 130.33, 129.50, 127.4, 126.8, 124.5, 124.1, 120.1, 119.0, 111.6, 77.2, 30.5, 11.2; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{20}\text{BrN}_5\text{O}_2$ [$\text{M}+\text{H}$]⁺ 466.0873; found 466.0878.

4-(1-(3,5-dimethyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3-(3-fluorophenyl)-1-phenyl-1*H*-pyrazole (5d)




Off-white solid; 82% yield; mp. 88–90°C; $[\alpha]_D^{25} = +60.00$ (c 0.2, CHCl₃); 96% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 13.63 min (minor) and t_R = 19.42 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.71 – 7.68 (m, 2H), 7.48 – 7.44 (m, 2H), 7.42 – 7.28 (m, 4H), 7.10 – 7.05 (m, 1H), 5.72 (s, 1H), 5.02 – 4.97 (m, 1H), 4.85 (dd, J = 12.4, 7.4 Hz, 1H), 4.72 (dd, J = 12.3, 9.1 Hz, 1H), 2.16 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 162.8 (d, J = 244.9 Hz), 150.3, 142.4, 139.5, 134.9 (d, J = 8.3 Hz), 130.3 (d, J = 8.3 Hz), 129.5, 126.9, 126.1, 123.6, 119.1, 118.5, 115.5, 115.3, 115.1, 111.6, 77.6, 30.8, 11.6; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀FN₅O₂ [M+H]⁺ 406.1674; found 406.1680.

3-(3-chlorophenyl)-4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1H-pyrazole (5e)




Off-white solid; 71% yield; mp. 84–85°C; $[\alpha]_D^{25} = +73.33$ (c 0.15, CHCl₃); 98% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 90:10, 1 mL/min, 254 nm, t_R = 15.62 min (minor) and t_R = 19.39 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.71 – 7.68 (m, 2H), 7.51 – 7.43 (m, 4H), 7.34 – 7.29 (m, 3H), 6.38 (s, 1H), 4.99 – 4.95 (m, 1H), 4.85 (dd, J = 12.3, 7.6 Hz, 1H), 4.71 (dd, J = 12.3, 8.8 Hz, 1H), 2.14 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.3, 142.4, 139.6, 134.7, 134.5, 130.0, 129.6, 128.5, 128.3, 127.0, 126.2, 126.1, 119.2, 118.7, 111.6, 77.8, 30.9, 11.6; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀ClN₅O₂ [M+Na]⁺ 444.1198; found 444.1188.

3-(3-bromophenyl)-4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1H-pyrazole (5f)




Off-white solid; 52% yield; mp. 91–92°C; $[\alpha]_D^{25} = +60.00$ (c 0.15, CHCl₃); >99% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 90:10, 1 mL/min, 254 nm, t_R = 18.14 min (minor) and t_R = 24.19 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, J = 0.68 Hz, 1H), 7.71 – 7.69 (m, 2H), 7.65 (t, J = 1.76 Hz, 1H), 7.51 – 7.45 (m, 4H), 7.34 – 7.25 (m, 2H), 4.98 – 4.94 (m, 1H), 4.86 (dd, J = 12.3, 7.7 Hz, 1H), 4.71 (dd, J = 12.3, 8.7 Hz, 1H), 2.15 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 139.5, 134.9, 131.4, 131.1, 130.1, 129.5, 127.0, 126.61, 125.9, 122.6, 119.1, 118.6, 111.5, 77.7, 30.8, 11.6; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀BrN₅O₂ [M+Na]⁺ 488.0693; found 488.0732.

3-(4-fluorophenyl)-4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1H-pyrazole (5g)




Off-white solid; 66% yield; mp. 86–87°C; $[\alpha]_D^{25} = +50.00$ (c 0.2, CHCl₃); >99% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 90:10, 0.5 mL/min, 254 nm, t_R = 41.25 min (minor) and t_R = 44.21 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.67 – 7.67 (m, 2H), 7.52 – 7.49 (m, 2H), 7.46 – 7.42 (m, 2H), 7.31 – 7.25 (m, 1H), 7.11 – 7.07 (m, 2H), 4.95 (dd, J = 8.6, 7.8 Hz, 1H), 4.82 (dd, J = 12.3, 7.4 Hz, 1H), 4.70 (dd, J = 12.3, 9.2 Hz, 1H), 2.12 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 164.0, 161.5, 150.7, 142.2, 139.6, 129.9 (d, J = 32.2), 129.5, 129.0 (d, J = 11.8), 126.8, 125.9, 119.0, 118.5, 115.7, 115.5, 111.6, 77.5, 30.8, 11.4; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀FN₅O₂ [M+H]⁺ 406.1674; found 406.1680.

3-(4-chlorophenyl)-4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1H-pyrazole (5h)




Off-white solid; 50% yield; mp. 95–96°C; $[\alpha]_D^{25} = +25.00$ (c 0.2, CHCl₃); 98% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 90:10, 1 mL/min, 254 nm, t_R = 15.43 min (minor) and t_R = 17.38 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.69 – 7.67 (m, 2H), 7.51 – 7.48 (m, 2H), 7.47 – 7.43 (m, 2H), 7.40 – 7.37 (m, 2H), 7.32 – 7.29 (m, 1H), 5.84 (s, 1H), 4.99 – 4.94 (m, 1H), 4.82 (dd, J = 12.3, 7.4 Hz, 1H), 4.70 (dd, J = 12.3, 9.1 Hz, 1H), 2.15 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.4, 142.4, 139.6, 134.5, 131.4, 129.5, 129.4, 128.9, 126.9, 126.1, 119.1, 118.5, 111.7, 77.5, 30.9, 11.6; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀ClN₅O₂ [M+H]⁺ 422.1378; found 422.1326.

3-(4-bromophenyl)-4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1H-pyrazole (5i)




White solid; 75% yield; mp. 84–85°C; $[\alpha]_D^{25} = +20.00$ (c 0.1, CHCl₃); 93% ee; HPLC [Daicel Chiralpak IE, hexane/i-PrOH, 90:10, 1 mL/min, 254 nm, t_R = 16.38 min (minor) and t_R = 19.86 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.69 – 7.67 (m, 2H), 7.57 – 7.54 (m, 2H), 7.48 – 7.42 (m, 4H), 7.33 – 7.29 (m, 1H), 5.00 – 4.94 (m, 1H), 4.83 (dd, J = 12.4, 7.4 Hz, 1H), 4.71 (dd, J = 12.4, 9.1 Hz, 1H), 4.33 (br s, 1H), 2.15 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.4, 142.4, 139.6, 131.8, 129.6, 129.5, 126.9, 126.1, 122.7, 119.1, 118.5, 111.7, 77.5, 30.9, 11.6; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₂₀BrN₅O₂ [M+H]⁺ 466.0873; found 466.0836.

3-(2,4-dichlorophenyl)-4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-1H-pyrazole (5j)




Dirty white solid; 62% yield; mp. 99–100°C; $[\alpha]_D^{25} = +46.67$ (c 0.15, CHCl₃); 90% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 80:20, 1 mL/min, 254 nm, t_R = 11.78 min (minor) and t_R = 23.00 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J = 0.4 Hz, 1H), 7.69 – 7.67 (m, 2H), 7.48 – 7.44 (m, 3H), 7.34 – 7.29 (m, 1H), 7.24 (dd, J = 8.2, 2.1 Hz, 1H), 7.14 – 7.08 (m, 2H), 4.96 (s, 1H), 4.86 – 4.79 (m, 2H), 4.76 – 4.70 (m, 1H), 2.01 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 148.9, 142.2, 139.5, 135.4, 134.2, 132.4, 130.7, 129.5, 129.3, 127.1, 127.0, 125.8, 124.6, 120.5, 119.1, 111.7, 77.2, 30.5, 19.7, 11.2; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₁₉Cl₂N₅O₂ [M+H]⁺ 456.0989; found 456.0991.

4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole (5k)



Off-white solid; 81% yield; mp. 93–94°C; $[\alpha]_D^{25} = +26.67$ (c 0.15, CHCl₃); 95% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 16.13 min (minor) and t_R = 17.65 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (s, 1H), 7.69 – 7.67 (m, 2H), 7.50 – 7.48 (m, 2H), 7.45 – 7.41 (m, 2H), 7.30 – 7.28 (m, 1H), 7.26 – 7.23 (m, 2H), 6.53 (s, 1H), 5.02 (dd, J = 9.7, 6.9 Hz, 1H), 4.80 (dd, J = 12.4, 6.8 Hz, 1H), 4.69 (dd, J = 12.3, 9.8 Hz, 1H), 2.38 (s, 3H), 2.18 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 151.5, 142.4, 139.7, 138.3, 129.9, 129.4, 127.8, 126.6, 126.2, 118.9, 118.3, 111.8, 77.2, 30.8, 21.3, 11.6; HRMS (ESI-TOF) m/z: calcd. for C₂₃H₂₃N₅O₂ [M+H]⁺ 402.1925; found 402.1934.


4-(1-(3,5-dimethyl-1H-pyrazol-4-yl)-2-nitroethyl)-3-(2-methoxyphenyl)-1-phenyl-1H-pyrazole (5l)



Off-white solid; 71% yield; mp. 89–90°C; $[\alpha]_D^{25} = +10.00$ (c 0.2, CHCl₃); 91% ee; HPLC [Chiralpak IC, hexane/i-PrOH, 75:25, 1 mL/min, 254 nm, t_R = 30.38 min (minor) and t_R = 59.62 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.66 (m, 2H), 7.63 (d, J = 0.8 Hz, 1H), 7.45 – 7.38 (m, 4H), 7.29 – 7.24 (m, 1H), 7.04 – 6.98 (m, 2H), 5.04 – 5.00 (m, 1H), 4.71 – 4.64 (m, 2H), 3.90 (s, 3H),


3.36 (s, 1H), 2.12 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.1, 149.4, 142.5, 139.8, 131.4, 130.4, 129.4, 126.4, 125.5, 121.9, 121.0, 120.7, 118.9, 110.7, 77.2, 55.5, 31.0, 11.4; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{23}\text{H}_{23}\text{N}_5\text{O}_3$ [$\text{M}+\text{H}$]⁺ 418.1874; found 418.1880.

4-(1-(3,5-dimethyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3-(4-methoxyphenyl)-1-phenyl-1*H*-pyrazole (5m)




Off-white solid; 63% yield; mp. 82–83°C; $[\alpha]_D^{25} = +10.00$ (c 0.1, CHCl_3); 94% ee; HPLC [Chiralpak IE, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 25.17$ min (minor) and $t_R = 29.68$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (s, 1H), 7.69 – 7.67 (m, 2H), 7.52 – 7.50 (m, 2H), 7.46 – 7.42 (m, 2H), 7.30 – 7.28 (m, 1H), 6.97 – 6.95 (m, 2H), 6.36 (s, 1H), 5.00 (dd, $J = 9.5, 7.0$ Hz, 1H), 4.81 (dd, $J = 12.4, 6.9$ Hz, 1H), 4.69 (dd, $J = 12.3, 9.7$ Hz, 1H), 3.84 (s, 3H), ^1H NMR (400 MHz, CDCl_3) δ 159.7, 151.3, 142.4, 139.7, 129.4, 129.3, 126.6, 126.1, 125.3, 118.9, 118.2, 114.2, 11.6; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O}_3$ [$\text{M}+\text{H}]^+$ 418.1874; found 418.1880.

4-(1-(3,5-dimethyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3-(naphthalen-2-yl)-1-phenyl-1*H*-pyrazole (5o)




White solid; 77% yield; mp. 98–100°C; $[\alpha]_D^{25} = +6.7$ (c 0.15, CHCl_3); 92% ee; HPLC [Chiralpak IE, hexane/i-PrOH, 90:10, 1 mL/min, 254 nm, $t_R = 23.58$ min (minor) and $t_R = 28.56$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 8.00 (s, 1H), 7.90 (d, $J = 8.5$ Hz, 1H), 7.86 – 7.82 (m, 2H), 7.80 (s, 1H), 7.77 – 7.75 (m, 1H), 7.74 – 7.71 (m, 2H), 7.52 – 7.48 (m, 3H), 7.47 – 7.44 (m, 2H), 7.33 – 7.29 (m, 1H), 5.12 (dd, $J = 8.9, 7.4$ Hz, 1H), 4.86 (dd, $J = 12.4, 7.2$ Hz, 1H), 4.70 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.4, 142.5, 139.7, 133.3, 133.1, 130.3, 129.5, 128.4, 126.5, 126.3, 125.8, 119.1, 118.7, 111.9, 77.5, 31.1, 11.6; HRMS (ESI-TOF) m/z: calcd. for 5; found 438.1923.

General procedure for the synthesis of 6



To a stirred solution of **3** (0.1 mmol) in ethanol was added hydroxyl amine hydrochloride (0.15 mmol, 1.5 equiv.). The reaction mixture was carried out at 60 °C for 12h, after which the solvent was reduced under pressure, and the crude reaction mixture was purified by column chromatography on silica gel (mesh 60–120) using *n*-hexane:ethyl acetate (85:15) as the eluents to afford the final adduct **6**.


4-(1-(1,3-diphenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6a)



Off-white solid; 63% yield; mp. 124-126°C; $[\alpha]_D^{25} = +53.33$ (c 0.15, CHCl₃); 99% ee; HPLC [Chiralpak IA, hexane/i-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 9.97$ min (minor) and $t_R = 14.53$ min


(major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.78 (s, 1H), 7.71 – 7.68 (m, 2H), 7.52 – 7.40 (m, 7H), 7.34 – 7.30 (m, 1H), 4.94 (dd, J = 9.6, 6.9 Hz, 1H), 4.84 (dd, J = 12.5, 6.9 Hz, 1H), 4.70 (dd, J = 12.6, 9.5 Hz, 1H), 2.20 (s, 3H), 2.15 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.7, 158.5, 151.7, 139.5, 132.5, 129.5, 128.8, 128.7, 128.1, 127.0, 125.5, 119.1, 117.1, 110.6, 76.8, 29.9, 11.4, 10.8; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{20}\text{N}_4\text{O}_3$ [$\text{M}+\text{Na}]^+$ 411.1428; found 411.1307.

4-(1-(3-(2-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6b)




Off-white solid; 72% yield; mp. 138–140°C; $[\alpha]_D^{25} = +53.33$ (c 0.15, CHCl_3); 91% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 11.89 min (minor) and t_R = 17.98 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.84 (s, 1H), 7.71 – 7.69 (m, 2H), 7.49 – 7.45 (m, 3H), 7.39 – 7.28 (m, 3H), 7.23 (dd, J = 7.6, 1.7 Hz, 1H), 4.88 – 4.78 (m, 2H), 4.74 (dd, J = 9.5, 7.7 Hz, 1H), 2.05 (s, 3H), 2.03 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.7, 158.3, 149.9, 139.4, 133.9, 131.7, 131.6, 130.5, 129.7, 129.6, 127.1, 127.0, 124.3, 119.1, 118.8, 110.3, 76.6, 29.7, 10.9, 10.6; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{19}\text{ClN}_4\text{O}_3$ [$\text{M}+\text{Na}]^+$ 423.1218; found 423.1242.

4-(1-(3-(2-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6c)




Off-white solid; 80% yield; mp. 74–75°C; $[\alpha]_D^{25} = +113.33$ (c 0.15, CHCl_3); 91% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 10.65 min (minor) and t_R = 14.84 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.84 (s, 1H), 7.72 – 7.69 (m, 2H), 7.68 – 7.66 (m, 1H), 7.49 – 7.45 (m, 2H), 7.37 – 7.27 (m, 3H), 7.19 (dd, J = 7.4, 1.9 Hz, 1H), 4.90 – 4.72 (m, 3H), 2.03 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 158.3, 151.4, 139.5, 133.8, 132.8, 131.6, 130.6, 129.6, 127.6, 127.0, 124.2, 123.9, 119.1, 118.5, 110.3, 76.6, 29.7, 10.9, 10.6; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{19}\text{BrN}_4\text{O}_3$ [$\text{M}+\text{Na}]^+$ 489.0533; found 489.0561.

4-(1-(3-(3-fluorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6d)



Off-white solid; 75% yield; mp. 85–86°C; $[\alpha]_D^{25} = +70.00$ (c 0.1, CHCl_3); 95% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 11.25 min (minor) and t_R = 15.34 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.82 (s, 1H), 7.71 – 7.68 (m, 2H), 7.50 – 7.46 (m, 2H), 7.44 – 7.39 (m, 1H), 7.36 – 7.29 (m, 2H), 7.28 – 7.24 (m, 1H), 7.14 – 7.08 (m, 1H), 4.94 (dd, J = 8.9, 7.3 Hz, 1H), 4.87 (dd, J = 12.5, 7.1 Hz, 1H), 4.72 (dd, J = 12.5, 9.1 Hz, 1H), 2.24 (s, 3H), 2.17 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 164.0, 161.6, 158.4, 150.3, 139.3, 134.6 (d, J = 8.0 Hz), 130.4 (d, J = 8.5 Hz), 129.6, 127.2, 125.7, 123.6 (d, J = 2.7 Hz), 119.1, 117.1, 115.8, 115.6, 115.1, 110.4, 76.9, 29.9, 11.4, 10.9; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{19}\text{FN}_4\text{O}_3$ [$\text{M}+\text{H}]^+$ 407.1514; found 407.1544.


4-(1-(3-(3-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6e)



Off-white solid; 62% yield; mp. 125–126°C; $[\alpha]_D^{25} = +53.33$ (c 0.30, CHCl_3); 88% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 9.72 min (minor) and t_R = 12.83 min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.84 (s, 1H), 7.71 – 7.68 (m, 2H), 7.51 – 7.46 (m, 3H), 7.42 – 7.32 (m, 4H), 4.95 – 4.85 (m, 2H), 4.72 (dd, J = 11.9, 8.5 Hz, 1H), 2.24 (s, 3H), 2.16 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 158.3, 150.3, 139.4, 134.7, 134.2, 130.1, 129.6,


128.8, 128.2, 127.2, 126.1, 125.6, 119.2, 117.1, 110.4, 76.97, 29.9, 11.4, 10.8; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₁₉ClN₄O₃ [M+H]⁺ 423.1218; found 423.1200.

4-(1-(3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6h)




Light-yellow solid; 56% yield; mp. 136-137°C; $[\alpha]_D^{25} = +30.00$ (c 0.10, CHCl₃); 97% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 11.56 min (minor) and t_R = 26.32 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 0.7 Hz, 1H), 7.70 – 7.67 (m, 2H), 7.50 – 7.41 (m, 6H), 7.36 – 7.32 (m, 1H), 4.93 – 4.82 (m, 2H), 4.71 (dd, *J* = 12.3, 9.1 Hz, 1H), 2.24 (s, 3H), 2.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 158.4, 150.5, 139.4, 134.9, 131.0, 129.6, 129.4, 129.1, 127.2, 125.7, 119.1, 117.1, 110.5, 76.8, 29.9, 11.5, 10.9; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₁₉ClN₄O₃ [M+Na]⁺ 445.1038 found 445.1061.

4-(1-(3-(4-bromophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6i)




Pale-yellow solid; 70% yield; mp. 146-148°C; $[\alpha]_D^{25} = +13.33$ (c 0.15, CHCl₃); 93% ee; HPLC [Chiralpak IE, hexane/*i*-PrOH, 90:10, 1 mL/min, 254 nm, t_R = 15.99 min (minor) and t_R = 17.97 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 0.5 Hz, 1H), 7.69 – 7.67 (m, 2H), 7.59 – 7.57 (m, 2H), 7.50 – 7.45 (m, 2H), 7.41 – 7.39 (m, 2H), 7.36 – 7.31 (m, 1H), 4.93 – 4.82 (m, 2H), 4.71 (dd, *J* = 12.3, 9.1 Hz, 1H), 2.23 (s, 3H), 2.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 158.4, 150.5, 139.4, 132.0, 131.4, 129.6, 127.2, 125.8, 123.0, 119.1, 117.0, 110.5, 76.8, 29.9, 11.5, 10.9; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₁₉BrN₄O₃ [M+Na]⁺ 489.0533; found 489.0515.

4-(1-(3-(2,4-dichlorophenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6j)



Off-white solid; 73% yield; mp. 160-161°C; $[\alpha]_D^{25} = +70.00$ (c 0.20, CHCl₃); 95% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 80:20, 1 mL/min, 254 nm, t_R = 8.28 min (minor) and t_R = 11.98 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.70 – 7.68 (m, 2H), 7.51 – 7.46 (m, 3H), 7.36 – 7.32 (m, 1H), 7.30 (dd, *J* = 8.2, 2.0 Hz, 1H), 7.17 (d, *J* = 8.2 Hz, 1H), 4.88 – 4.71 (m, 3H), 2.09 (s, 3H), 2.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 158.2, 148.8, 139.3, 135.8, 134.7, 132.3, 130.3, 129.6, 129.5, 127.4, 127.2, 124.5, 119.1, 118.8, 110.2, 76.6, 29.7, 10.9, 10.6; HRMS (ESI-TOF) m/z: calcd. for C₂₂H₁₈Cl₂N₄O₃ [M+H]⁺ 457.0829; found 457.0830.


3,5-dimethyl-4-(2-nitro-1-(1-phenyl-3-(*p*-tolyl)-1*H*-pyrazol-4-yl)ethyl)isoxazole (6k)



Off-white solid; 73% yield; mp. 146-147°C; $[\alpha]_D^{25} = +33.33$ (c 0.15, CHCl₃); 90% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, t_R = 12.68 min (minor) and t_R = 26.26 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (s, 1H), 7.70 – 7.67 (m, 2H), 7.49 – 7.44 (m, 2H), 7.44 – 7.41 (m, 2H), 7.33 – 7.29 (m, 1H), 7.27 – 7.25 (m, 2H), 4.95 (dd, *J* = 9.9, 6.6 Hz, 1H), 4.83


(dd, $J = 12.6, 6.7$ Hz, 1H), 4.69 (dd, $J = 12.6, 9.8$ Hz, 1H), 2.40 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.7, 158.6, 151.7, 139.5, 138.7, 129.5, 127.9, 126.9, 125.6, 119.0, 116.9, 110.6, 77.2, 29.9, 21.3, 11.5, 10.9; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{23}\text{H}_{22}\text{N}_4\text{O}_3$ [$\text{M}+\text{H}]^+$ 403.1765; found 403.1750.

4-(1-(3-(4-methoxyphenyl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl)-3,5-dimethylisoxazole (6m)




Pale yellow solid; 63% yield; mp. 136–138°C; $[\alpha]_D^{25} = +32.00$ (c 0.125, CHCl_3); 96% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 80:20, 1 mL/min, 254 nm, $t_R = 10.73$ min (minor) and $t_R = 18.52$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.74 (s, 1H), 7.69 – 7.67 (m, 2H), 7.48 – 7.44 (m, 4H), 7.33 – 7.29 (m, 1H), 6.99 – 6.96 (m, 2H), 4.93 (dd, $J = 9.5, 6.8$ Hz, 1H), 4.84 (dd, $J = 12.6, 6.8$ Hz, 1H), 4.69 (dd, $J = 12.5, 9.6$ Hz, 1H), 3.85 (s, 3H), 2.24 (s, 3H), 2.18 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.7, 160.0, 158.5, 151.5, 139.5, 129.5, 129.3, 126.9, 125.5, 124.8, 119.0, 116.8, 114.3, 110.7, 76.8, 55.3, 29.96, 11.5, 10.9; HRMS (ESI-TOF) m/z: calcd. For $\text{C}_{23}\text{H}_{22}\text{N}_4\text{O}_4$ [$\text{M}+\text{Na}]^+$ 441.1533; found 441.1511.

3,5-dimethyl-4-(2-nitro-1-(3-(4-nitrophenyl)-1-phenyl-1*H*-pyrazol-4-yl)ethyl)isoxazole (6n)




Yellowish solid; 58% yield; mp. 208–210°C; $[\alpha]_D^{25} = +26.67$ (c 0.15, CHCl_3); 89% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 13.28$ min (minor) and $t_R = 29.57$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 8.32 – 8.29 (m, 2H), 7.88 (s, 1H), 7.76 – 7.74 (m, 2H), 7.72 – 7.70 (m, 2H), 7.53 – 7.49 (m, 2H), 7.40 – 7.36 (m, 1H), 4.99 – 4.95 (m, 1H), 4.88 (dd, $J = 12.5, 7.4$ Hz, 1H), 4.74 (dd, $J = 12.5, 8.7$ Hz, 1H), 2.26 (s, 3H), 2.18 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 158.3, 149.1, 147.7, 139.2, 139.0, 129.7, 128.6, 127.6, 126.2, 124.0, 119.3, 117.6, 110.3, 76.9, 30.0, 11.6, 11.0; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{22}\text{H}_{19}\text{N}_5\text{O}_5$ [$\text{M}+\text{H}]^+$ 434.1459; found 434.1446.

3,5-dimethyl-4-(1-(3-(naphthalen-2-yl)-1-phenyl-1*H*-pyrazol-4-yl)-2-nitroethyl) isoxazole (6o)



Off-white solid; 51% yield; mp. 105–107°C; $[\alpha]_D^{25} = +20.00$ (c 0.15, CHCl_3); 96% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 80:20, 1 mL/min, 254 nm, $t_R = 10.11$ min (minor) and $t_R = 15.30$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.97 (d, $J = 1.1$ Hz, 1H), 7.92 (d, $J = 8.6$ Hz, 1H), 7.89 – 7.85 (m, 2H), 7.81 (d, $J = 0.8$ Hz, 1H), 7.74 – 7.72 (m, 2H), 7.69 (dd, $J = 8.5, 1.7$ Hz, 1H), 7.54 – 7.46 (m, 4H), 7.36 – 7.32 (m, 1H), 5.07 – 5.03 (m, 1H), 4.88 (dd, $J = 12.6, 6.9$ Hz, 1H), 4.71 (dd, $J = 12.6, 9.5$ Hz, 1H), 2.21 (s, 3H), 2.19 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 158.5, 151.5, 139.5, 133.2, 133.1, 129.9, 129.6, 128.7, 128.2, 127.8, 127.2, 127.1, 126.7, 125.8, 125.6, 119.1, 117.2, 110.7, 76.9, 30.2, 11.5, 10.9; HRMS (ESI-TOF) m/z: calcd. for $\text{C}_{26}\text{H}_{22}\text{N}_4\text{O}_3$ [$\text{M}+\text{Na}]^+$ 461.1584; found 461.1593.


3,5-dimethyl-4-(2-nitro-1-(1-phenyl-3-(thiophen-2-yl)-1*H*-pyrazol-4-yl)ethyl)isoxazole (6p)



Light yellowish solid; 59% yield; mp. 119–120°C; $[\alpha]_D^{25} = +20.00$ (c 0.2, CHCl_3); 93% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 85:15, 1 mL/min, 254 nm, $t_R = 11.81$ min (minor) and $t_R = 16.06$ min (major)]; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (s, 1H), 7.69 – 7.67 (m, 2H), 7.49 – 7.45 (m, 2H), 7.39 (dd, $J = 5.1, 0.9$ Hz, 1H), 7.35 – 7.31 (m, 1H), 7.29 (dd, $J = 3.6, 0.9$ Hz, 1H), 7.13 (dd, $J = 5.0, 3.6$ Hz, 1H), 5.01 (dd, $J = 9.6, 6.5$ Hz, 1H), 4.93 (dd, $J = 12.7, 6.6$ Hz, 1H), 4.76 (dd, $J = 12.6, 9.6$ Hz, 1H), 2.32 (s, 3H), 2.25 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 158.7, 145.6, 139.3, 133.9, 129.6, 127.8,


127.2, 126.5, 126.2, 125.8, 119.1, 116.9, 110.4, 76.6, 30.2, 11.8, 11.0; HRMS (ESI-TOF) m/z: calcd. for $C_{20}H_{18}N_4O_3S$ [M+H]⁺ 395.1172; found 395.1161.

General procedure for synthesis of 7




To a suspension of **6a** (0.1 mmol, 1 equiv.) and nickel chloride hexahydrate (0.1 mmol, 1 equiv.) in methanol (5 mL) was added sodium borohydride (1.2 mmol, 12 equiv.) at 0 °C and the mixture was stirred at room temperature for 1 h, after which the mixture was quenched with sat. NH₄Cl at 0 °C and extracted with dichloromethane. The combined organic layers were washed with brine and dried over Na₂SO₄ and concentrated under vacuum to give the corresponding amine. The crude amine was then dissolved in CH₂Cl₂ (5 mL) at 0 °C followed by adding of Et₃N (0.1 mmol, 14 uL). The resulting mixture was stirred at 0 °C for 10 min, then a solution of TsCl (0.15 mmol, 28.6 mg) in dry CH₂Cl₂ (1.0 mL) was added dropwise. The resulting solution was stirred at 0 °C for 30 min, then was allowed to warm to room temperature; stirring was then continued for about 4 h. The reaction mixture was concentrated under vacuum and purified by column chromatography on silica gel (mesh 60–120) using *n*-hexane:ethyl acetate (85:15) as the eluents to afford **7**.

N-(2-(3,5-dimethylisoxazol-4-yl)-2-(1,3-diphenyl-1*H*-pyrazol-4-yl)ethyl)-4-methylbenzenesulfonamide (7)



Pale-yellow solid; 60% yield; mp. 70–71 °C; $[\alpha]_D^{25} = +6.67$ (c 0.15, CHCl₃); 99% ee; HPLC [Chiralpak IA, hexane/*i*-PrOH, 75:25, 1 mL/min, 254 nm, t_R = 21.99 min (minor) and t_R = 26.28 min (major)]; ¹H NMR (400 MHz, CDCl₃) δ 7.70 – 7.68 (m, 2H), 7.60 (s, 1H), 7.58 – 7.56 (m, 2H), 7.54 – 7.51 (m, 2H), 7.46 – 7.43 (m, 2H), 7.42 – 7.38 (m, 2H), 7.31 – 7.27 (m, 1H), 4.29 – 4.26 (m, 1H), 4.22 – 4.17 (m, 1H), 3.88 (dd, *J* = 10.6, 3.2 Hz, 1H), 2.38 (s, 3H), 2.35 (s, 3H), 2.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 153.0, 150.7, 145.1, 143.2, 139.6, 139.1, 135.3, 132.7, 130.1, 129.5, 128.9, 128.1, 127.1, 126.7, 125.6, 123.3, 122.1, 118.8, 58.0, 36.3, 23.5, 21.6, 15.6; HRMS (ESI-TOF) m/z: calcd. for $C_{29}H_{28}N_4O_3S$ [M+H]⁺ 513.1955; found 513.1850.

Single crystal X-ray diffraction analysis and crystal data of (3b)



Empirical formula	C ₂₂ H ₂₀ ClN ₃ O ₄
Formula weight	425.86
Temperature/K	293.15K
Crystal system	monoclinic
Space group	P21
a/Å	7.7803(2)
b/Å	9.3559(3)
c/Å	14.8204(4)
α/°	90
β/°	90.009 (3)
γ/°	90
Volume/Å ³	1078.80 (5)
Z	2
ρcalcg/cm ³	1.311
μ/mm ⁻¹	0.210
F(000)	444.0
Crystal size/mm ³	0.25 × 0.12 × 0.10
Radiation	MoKα ($\lambda = 0.71073$)
2Θ range for data collection/°	6.812 to 54.934
Index ranges	-10 ≤ h ≤ 9, -12 ≤ k ≤ 11, -19 ≤ l ≤ 15
Reflections collected	14001
Independent reflections	4537 [R _{int} = 0.0838, R _{sigma} = 0.0518]
Data/restraints/parameters	4537/1/273
Goodness-of-fit on F2	1.087
Final R indexes [I>=2σ (I)]	R1 = 0.0561, wR2 = 0.1366
Final R indexes [all data]	R1 = 0.0806, wR2 = 0.1700
Largest diff. peak/hole / e Å ⁻³	0.15/-0.28
Flack parameter	0.14 (7)

Table 2 Fractional Atomic Coordinates ($\times 10^4$) and Equivalent Isotropic Displacement Parameters ($\text{\AA}^2 \times 10^3$) for sub-GNDU2. U_{eq} is defined as 1/3 of the trace of the orthogonalised U_{IJ} tensor.

Atom	x	y	z	U(eq)
C11	6643.5 (18)	2760 (2)	907 (1)	107.6 (6)
O3	9420 (4)	1430 (4)	3851 (2)	77.5 (9)
N2	5525 (4)	6873 (4)	2292 (2)	54.0 (8)
N1	6587 (4)	6500 (4)	1606 (2)	56.7 (8)
N3	9675 (6)	5801 (5)	4250 (3)	73.8 (11)
C13	7911 (5)	1344 (5)	3709 (3)	58.7 (10)
O1	9199 (6)	7014 (4)	4342 (3)	111.9 (14)
C3	5810 (5)	6094 (5)	3040 (3)	56.3 (10)
C2	7123 (5)	5165 (4)	2854 (2)	50.5 (9)
C1	7554 (5)	5468 (5)	1949 (2)	52.8 (9)
C17	4258 (5)	7963 (5)	2160 (3)	56.4 (9)
C12	6855 (5)	2665 (5)	3467 (2)	52.1 (9)
C4	8937 (5)	4785 (5)	1418 (2)	54 (1)
O4	5476 (5)	2810 (7)	4877 (3)	112.7 (15)
O2	11120 (6)	5478 (5)	4035 (3)	108.9 (14)
C10	7930 (5)	4038 (5)	3433 (2)	49.9 (9)
C5	10584 (6)	5343 (6)	1422 (3)	73.4 (13)
C15	5282 (5)	2747 (6)	4082 (4)	71.7 (12)
C9	8664 (6)	3565 (6)	917 (3)	68.2 (12)
C18	2970 (5)	8134 (5)	2783 (3)	71.3 (13)
C20	1837 (8)	10043 (7)	1918 (4)	96.3 (17)
C11	8392 (5)	4619 (5)	4372 (3)	58.3 (10)
C19	1758 (7)	9184 (7)	2651 (4)	91.1 (16)
C22	4336 (7)	8811 (7)	1409 (3)	85.4 (16)
C6	11895 (7)	4734 (8)	931 (4)	93.1 (19)
C8	9980 (8)	2928 (8)	417 (3)	91.1 (17)
C21	3099 (9)	9867 (8)	1295 (4)	106 (2)
C7	11590 (8)	3549 (8)	434 (4)	94.0 (19)
C14	7026 (8)	-41 (7)	3724 (6)	112 (2)
C16	3557 (6)	2727 (10)	3631 (5)	115 (2)

Table 3 Anisotropic Displacement Parameters ($\text{\AA}^2 \times 10^3$) for sub-GNDU2.**The Anisotropic displacement factor exponent takes the form: $-2\pi^2$** **[$h^2a^{*2}U_{11} + 2hka^*b^*U_{12} + \dots$].**

Atom	U11	U22	U33	U23	U13	U12
C11	100.3(10)	128.2(14)	94.3(9)	-42.4(9)	11.3(7)	-24(1)
O3	58.3(18)	64(2)	110(2)	-0.7(18)	2.1(16)	12.2(15)
N2	56.3(17)	54(2)	51.8(16)	3.3(15)	7.1(14)	8.3(15)
N1	58.7(18)	62(2)	49.4(16)	4.8(16)	8.2(14)	11.2(17)
N3	83(3)	58(3)	81(2)	1(2)	-17(2)	-2(2)
C13	56(2)	54(2)	66(2)	0(2)	8.2(19)	8(2)
O1	136(3)	52(2)	147(4)	-5(2)	-42(3)	1(2)
C3	59(2)	60(3)	50.0(19)	-0.9(19)	12.3(17)	11.9(19)
C2	50.5(19)	54(2)	47.3(18)	1.1(17)	7.3(15)	6.1(17)
C1	56(2)	54(2)	48.1(18)	1.6(18)	6.7(16)	2.5(19)
C17	61(2)	46(2)	62(2)	-5.1(18)	-0.6(17)	12.3(18)
C12	51.5(19)	53(2)	51.5(19)	0.6(18)	2.6(15)	1.9(18)
C4	57(2)	61(3)	44.1(17)	5.9(19)	10.5(16)	10.5(19)
O4	87(2)	173(5)	79(2)	-6(3)	35.6(18)	-11(3)
O2	86(3)	95(3)	145(4)	-7(3)	20(2)	-20(2)
C10	51.0(19)	53(2)	45.7(18)	4.2(17)	7.3(15)	10.0(17)
C5	62(3)	81(3)	77(3)	5(3)	18(2)	4(2)
C15	55(2)	72(3)	88(3)	4(3)	13(2)	1(2)
C9	71(3)	80(3)	53(2)	-3(2)	8(2)	8(2)
C18	63(3)	71(3)	79(3)	2(3)	11(2)	13(2)
C20	99(4)	86(4)	104(4)	-4(4)	0(3)	42(3)
C11	62(2)	60(3)	53(2)	2.0(19)	0.2(18)	1(2)
C19	79(3)	87(4)	107(4)	-3(4)	18(3)	29(3)
C22	100(4)	86(4)	70(3)	14(3)	15(2)	38(3)
C6	70(3)	106(5)	103(4)	15(4)	28(3)	17(3)
C8	110(4)	92(4)	71(3)	-17(3)	21(3)	25(4)
C21	131(5)	99(5)	89(4)	28(3)	6(4)	53(4)
C7	85(4)	108(5)	89(4)	16(4)	40(3)	33(4)
C14	90(4)	60(4)	186(7)	18(4)	-15(4)	-9(3)
C16	50(3)	128(6)	168(6)	0(5)	-1(3)	8(3)

Table 4 Bond Lengths for sub-GNDU2.

Atom	Atom	Length/Å	Atom	Atom	Length/Å
C11	C9	1.743 (5)	C17	C22	1.369 (7)
O3	C13	1.195 (5)	C12	C10	1.533 (6)
N2	N1	1.356 (4)	C12	C15	1.528 (6)
N2	C3	1.346 (5)	C4	C5	1.384 (6)
N2	C17	1.432 (5)	C4	C9	1.378 (7)
N1	C1	1.325 (5)	O4	C15	1.189 (6)
N3	O1	1.201 (6)	C10	C11	1.536 (6)
N3	O2	1.206 (6)	C5	C6	1.377 (7)
N3	C11	1.501 (6)	C15	C16	1.499 (7)
C13	C12	1.527 (6)	C9	C8	1.397 (7)
C13	C14	1.467 (8)	C18	C19	1.376 (7)
C3	C2	1.369 (5)	C20	C19	1.353 (9)
C2	C1	1.411 (5)	C20	C21	1.358 (9)
C2	C10	1.498 (6)	C22	C21	1.389 (8)
C1	C4	1.479 (5)	C6	C7	1.352 (10)
C17	C18	1.372 (6)	C8	C7	1.381 (9)

Table 5 Bond Angles for sub-GNDU2.


Atom	Atom	Atom	Angle/ [°]	Atom	Atom	Atom	Angle/ [°]
N1	N2	C17	120.1 (3)	C5	C4	C1	120.5 (4)
C3	N2	N1	112.2 (3)	C9	C4	C1	122.2 (4)
C3	N2	C17	127.7 (3)	C9	C4	C5	117.3 (4)
C1	N1	N2	104.2 (3)	C2	C10	C12	112.3 (3)
O1	N3	O2	123.6 (5)	C2	C10	C11	111.6 (4)
O1	N3	C11	118.5 (5)	C12	C10	C11	113.3 (3)
O2	N3	C11	117.9 (4)	C6	C5	C4	121.8 (6)
O3	C13	C12	121.0 (4)	O4	C15	C12	119.4 (4)
O3	C13	C14	121.2 (4)	O4	C15	C16	123.8 (5)
C14	C13	C12	117.8 (4)	C16	C15	C12	116.8 (5)
N2	C3	C2	107.5 (3)	C4	C9	C11	120.1 (3)
C3	C2	C1	103.9 (3)	C4	C9	C8	121.7 (5)
C3	C2	C10	130.1 (3)	C8	C9	C11	118.2 (4)
C1	C2	C10	125.9 (3)	C17	C18	C19	119.2 (5)
N1	C1	C2	112.1 (3)	C19	C20	C21	120.4 (5)
N1	C1	C4	121.5 (3)	N3	C11	C10	107.9 (3)
C2	C1	C4	126.3 (4)	C20	C19	C18	120.5 (5)
C18	C17	N2	119.6 (4)	C17	C22	C21	118.7 (5)
C22	C17	N2	119.5 (4)	C7	C6	C5	119.8 (6)
C22	C17	C18	120.9 (4)	C7	C8	C9	118.4 (6)
C13	C12	C10	113.1 (3)	C20	C21	C22	120.4 (6)
C13	C12	C15	109.3 (3)	C6	C7	C8	120.9 (5)
C15	C12	C10	114.5 (4)				



**Table 6 Hydrogen Atom Coordinates ($\text{\AA} \times 10^4$)
and Isotropic Displacement Parameters
($\text{\AA}^2 \times 10^3$) for sub- GNDU2.**



Atom	x	y	z	U(eq)
H3	5223.06	6171.57	3584.08	68
H12	6419.72	2509.02	2853.92	63
H10	9019.08	3782.72	3142.74	60
H5	10811.29	6152.68	1766.66	88
H18	2917.75	7547.14	3289.12	86
H20	1021	10759.13	1839.59	116
H11A	7370.29	4979.17	4669.95	70
H11B	8879.31	3864.37	4740.51	70
H19	877.47	9304.47	3068.6	109
H22	5199.67	8682.85	982.46	103
H6	12988.07	5135.76	941.98	112
H8	9776.6	2104.76	82.01	109
H21	3136.61	10456.48	790.4	128
H7	12475.91	3147.75	97.69	113
H14A	7857.75	-794.69	3772.43	168
H14B	6378.35	-156.95	3177.64	168
H14C	6261.92	-76.89	4232.43	168
H16A	3555.9	3389.85	3136.08	173
H16B	2688.32	2997.15	4057.97	173
H16C	3322.95	1782.92	3409.69	173



¹H and ¹³C NMR spectra


¹H and ¹³C NMR spectra of Michael adduct 3a-3q































































¹H and ¹³C NMR spectra of series 4



































































¹H and ¹³C NMR spectra of 5























































¹H and ¹³C NMR spectra of 6

















































HPLC chromatograms

HPLC chromatogram of Michael adducts 3a-3q






1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret Time	Area	Height	Area %	Height %
1	8.174	7885171	479780	50.046	61.473
2	10.950	7870631	300690	49.954	38.527
Total		15755803	780470	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.179	419791	31466	1.818	3.529
2	10.934	22672258	860275	98.182	96.471
Total		23092049	891741	100.000	100.000



1 PDA Multi 1/254nm 4nm

PeakTable



PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.674	3374260	184889	50.080	59.989
2	17.932	3363453	123317	49.920	40.011
Total		6737713	308206	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.113	3710613	178516	4.097	9.084
2	18.838	86857086	1786644	95.903	90.916
Total		90567699	1965160	100.000	100.000






PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.192	12277351	551320	50.152	55.443
2	15.137	12202993	443076	49.848	44.557
Total		24480345	994396	100.000	100.000



PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.926	1352056	74560	3.129	5.495
2	16.126	41859087	1282185	96.871	94.505
Total		43211143	1356744	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.957	22593042	1053220	50.265	54.232
2	14.180	22354714	888856	49.735	45.768
Total		44947756	1942076	100.000	100.000




1 PDA Multi 1/254nm 4nm


PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.906	1178372	61741	2.067	3.524
2	14.937	55841723	1690043	97.933	96.476
Total		57020095	1751785	100.000	100.000



PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.065	22453408	1226254	49.814	59.505
2	15.255	22621160	834514	50.186	40.495
Total		45074568	2060768	100.000	100.000



PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.189	5139200	351525	5.172	13.769
2	15.432	94233537	2201463	94.828	86.231
Total		99372738	2552988	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.785	11061522	564117	50.566	69.015
2	20.131	10814105	253261	49.434	30.985
Total		21875627	817378	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.726	976950	50367	2.401	5.056
2	19.597	39717651	945760	97.599	94.944
Total		40694601	996127	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.385	11323743	420477	50.475	66.857
2	32.450	11110407	208447	49.525	33.143
Total		22434150	628924	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable


PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.316	1594865	72402	2.856	7.156
2	31.555	54246832	939398	97.144	92.844
Total		55841696	1011800	100.000	100.000




PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.935	43322120	1458763	49.876	52.450
2	14.025	43537565	1322482	50.124	47.550
Total		86859686	2781245	100.000	100.000



PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.023	214243	11837	1.379	2.123
2	14.008	15322125	545656	98.621	97.877
Total		15536368	557493	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.847	12687559	482270	49.804	68.042
2	30.003	12787349	226507	50.196	31.958
Total		25474908	708777	100.000	100.000





1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.929	1217709	42613	4.003	7.517
2	29.672	29202678	524303	95.997	92.483
Total		30420387	566916	100.000	100.000



PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.325	1033519	67932	2.355	4.442
2	12.992	42846372	1461474	97.645	95.558
Total		43879891	1529405	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.648	16569654	403471	50.597	63.566
2	39.229	16178615	231257	49.403	36.434
Total		32748269	634728	100.000	100.000




1 PDA Multi 1/254nm 4nm


PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.035	2618432	68810	4.913	9.082
2	38.818	50676460	688820	95.087	90.918
Total		53294892	757630	100.000	100.000



PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	30.833	11950170	158273	49.623	55.397
2	47.283	12131540	127435	50.377	44.603
Total		24081710	285708	100.000	100.000



PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	31.245	1912858	25715	2.564	3.626
2	45.946	72686868	683499	97.436	96.374
Total		74599726	709214	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.539	18477473	961949	50.760	64.924
2	16.568	17923905	519694	49.240	35.076
Total		36401378	1481643	100.000	100.000

D:\HPLC\Bann\pyzNO2+AA\old hplc\512, IA, 1ml, 15%, naph s1 ch01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.490	4160715	186779	3.547	7.842
2	16.231	113126302	2195010	96.453	92.158
Total		117287017	2381789	100.000	100.000



1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.108	9731702	434304	50.022	53.120
2	12.523	9722992	383282	49.978	46.880
Total		19454693	817586	100.000	100.000





1 PDA Multi 1/254nm 4nm


PeakTable

PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.971	556848	31115	1.318	2.136
2	12.213	41680458	1425566	98.682	97.864
Total		42237306	1456681	100.000	100.000

HPLC chromatogram of bis-pyrazole derivatives 4



D:\...\Banni\pyzNO2+AA\second step bispyrazole\subs scope\465, IA, 1ml, 15%, pyzNO2+AA+PH, 2-Cl rac01.lcd
mAU




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.710	11859501	587160	50.220	59.235
2	13.572	11755368	404078	49.780	40.765
Total		23614869	991237	100.000	100.000

D:\...\Banni\pyzNO2+AA\second step bispyrazole\subs scope\466, IA, 1ml, 15%, pyzNO2+AA+PH, 2-Cl ch01.lcd
mAU




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.821	12115	912	1.446	2.770
2	13.614	825938	32019	98.554	97.230
Total		838053	32931	100.000	100.000

D:\HPLC\Bann\pyzNO2+AA\second step bispyrazole\subs scope\539 b,IA, 1ml, 15%, 2-Br rac rep0001.lcd
mAU




PDA Ch1 254nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.622	5088668	259699	50.464	60.725
2	17.763	4995088	167966	49.536	39.275
Total		10083756	427665	100.000	100.000

mAU

D:\HPLC\Bann\pyzNO2+AA\revised rawww\BP-575-B, IA, 1ml, 15% 2-Br ch.lcd




PDA Ch1 254nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.253	368845	18493	3.502	6.572
2	18.144	10163742	262909	96.498	93.428
Total		10532586	281402	100.000	100.000

D:\...\Banni\pyzNO2+AA\second step bispyrazole\subs scope\467, IA, 1ml, 15%, pyzNO2+AA+PH, 3-F rac01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.234	7859310	435093	49.022	53.960
2	9.896	8172739	371229	50.978	46.040
Total		16032049	806323	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\502b, IA, 1ml, 15%, 3-Fs2 ch01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.551	521467	38135	1.588	2.720
2	10.324	32326008	1363693	98.412	97.280
Total		32847474	1401828	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.986	3747827	193123	49.360	53.896
2	12.453	3845002	165202	50.640	46.104
Total		7592830	358325	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.175	99330	6031	2.591	3.991
2	12.683	3734916	145085	97.409	96.009
Total		3834246	151117	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\460, IA, 1ml, 15%, pyzNO2+AA+PH, 3-Br rac02.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.357	6868655	361393	48.152	50.337
2	9.882	7395959	356552	51.848	49.663
Total		14264614	717944	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\504b, IA, 1ml, 15%, 3-Br s2 ch01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.845	293770	17685	1.152	1.604
2	10.445	25198287	1084642	98.848	98.396
Total		25492057	1102327	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.549	24188331	1190397	48.774	59.725
2	17.253	25404328	802722	51.226	40.275
Total		49592659	1993119	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\555 b, IA, 1ml, 15%, 4-F s2 ch ree0001.lcd





1 PDA Multi 1/254nm 4nm


PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.229	2117026	132305	4.559	9.405
2	16.360	44322065	1274377	95.441	90.595
Total		46439091	1406682	100.000	100.000



D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\497b, IA, 1ml, 15%, 4-Br rac01.lcd




PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.201	4748000	244046	50.448	62.196
2	17.302	4663682	148333	49.552	37.804
Total		9411681	392379	100.000	100.000



D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\498b, IA, 1ml, 15%, 4-Br ch01.lcd




PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.237	1418817	79586	7.145	11.744
2	17.217	18439804	598073	92.855	88.256
Total		19858622	677659	100.000	100.000




D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\495b, IA, 1ml, 15% 4-Me s2 rac02.lcd



D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\496b, IA, 1ml, 15% 4-Me s2 ch01.lcd



D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\493b, IA, 1ml, 15%, 2-OMe rac01.lcd
mAU




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.042	14664437	742369	50.637	59.418
2	14.848	14295443	507032	49.363	40.582
Total		28959881	1249401	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\494b, IA, 1ml, 15%, 2-OMe ch01.lcd
mAU




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.129	170514	9440	1.874	2.898
2	14.921	8928878	316295	98.126	97.102
Total		9099392	325735	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\533B, IA, 1ml, 15%, 4-OMe s2 rac0001.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.128	6441336	235023	50.687	62.514
2	24.195	6266722	140930	49.313	37.486
Total		12708058	375953	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\534B, IA, 1ml, 15%, 4-OMe s2 ch0001.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.162	692785	27819	4.010	7.216
2	24.114	16585264	357718	95.990	92.784
Total		17278049	385537	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\507b, IA, 1ml, 15%, s2 racB01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.381	3371621	109653	50.320	60.494
2	25.636	3328763	71610	49.680	39.506
Total		6700384	181264	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\508b, IA, 1ml, 15%, s2 ch01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.604	737440	26424	2.609	4.515
2	24.692	27525839	558849	97.391	95.485
Total		28263278	585273	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\511b, IA, 1ml, 15%, naph s2 rac01.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.114	9666777	464245	50.245	57.522
2	14.795	9572339	342826	49.755	42.478
Total		19239116	807070	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\512b, IA, 1ml, 15%, naph s2 ch01.lcd





1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.067	136161	7824	0.997	1.504
2	14.573	13517629	512377	99.003	98.496
Total		13653791	520201	100.000	100.000




PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.862	922121	58211	2.404	3.665
2	11.871	37442683	1530288	97.596	96.335
Total		38364805	1588499	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\509b, IA, 1ml, 15%, 4-NO2 s2 rac02.lcd
mAU




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	20.309	10102902	229553	50.182	55.802
2	24.091	10029684	181821	49.818	44.198
Total		20132586	411375	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\second step bispyrazole\subs scope\510b, IA, 1ml, 15%, p-NO2 s2 ch01.lcd
mAU




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	20.402	3690829	95311	13.160	17.526
2	23.983	24354337	448505	86.840	82.474
Total		28045166	543816	100.000	100.000

HPLC chromatogram of series 5




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.721	7906560	318507	50.527	53.386
2	14.763	7741479	278100	49.473	46.614
Total		15648039	596607	100.000	100.000

D:\HPLC\Bann\pyzNO2+AA\second step bispyrazole\subs scope\582, IE, 1ml, 15%,t-a ch0001.lcd




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.888	1066999	49412	6.587	8.789
2	14.856	15130633	512825	93.413	91.211
Total		16197632	562237	100.000	100.000




1 PDA Multi 1/254nm 4nm

PDA Ch1 254nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.761	57511425	1383271	49.358	73.354
2	25.237	59006694	502482	50.642	26.646
Total		116518119	1885753	100.000	100.000




1 PDA Multi 1/254nm 4nm

PDA Ch1 254nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.843	2218388	68166	1.233	5.578
2	25.434	177689642	1153993	98.767	94.422
Total		179908030	1222159	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.901	31779687	829310	50.018	70.197
2	21.723	31756960	352091	49.982	29.803
Total		63536647	1181401	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable


PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.283	5731381	125525	5.048	11.474
2	22.467	107811150	968507	94.952	88.526
Total		113542532	1094032	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable					
PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.377	17464732	374898	50.638	60.903
2	19.819	17024968	240672	49.362	39.097
Total		34489700	615570	100.000	100.000



1 PDA Multi 1/254nm 4nm

PeakTable					
PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.628	830431	23875	1.949	4.019
2	19.421	41768669	570130	98.051	95.981
Total		42599101	594005	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.431	42416008	905512	49.429	55.813
2	19.557	43395670	716878	50.571	44.187
Total		85811678	1622389	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.623	776782	24311	0.900	1.901
2	19.387	85546387	1254817	99.100	98.099
Total		86323170	1279127	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	17.892	15992995	193114	49.179	55.724
2	25.192	16526858	153439	50.821	44.276
Total		32519853	346553	100.000	100.000

D:\HPLC\Banni\pyzNO2+AA\revised rawww\BP-835b, IE, 1ml, 10%.lcd







1 PDA Multi 1/254nm 4nm


PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.141	72791	880	0.053	0.100
2	24.193	136086909	875382	99.947	99.900
Total		136159700	876262	100.000	100.000








PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.352	19889055	430768	49.318	57.806
2	20.234	20438794	314433	50.682	42.194
Total		40327849	745201	100.000	100.000



PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.378	1556706	43053	3.507	6.215
2	19.856	42827016	649659	96.493	93.785
Total		44383722	692712	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.656	41173464	1219215	49.848	69.850
2	22.757	41424628	526272	50.152	30.150
Total		82598092	1745488	100.000	100.000






1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.778	903067	29099	4.820	12.510
2	22.998	17833632	203508	95.180	87.490
Total		18736700	232607	100.000	100.000






PeakTable

PDA Ch1 254nm 4nm



Peak#	Ret. Time	Area	Height	Area %	Height %
1	29.607	33996580	302395	49.623	70.077
2	62.598	34513061	129122	50.377	29.923
Total		68509640	431517	100.000	100.000




PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	30.382	3903815	37636	4.353	12.635
2	59.620	85772822	260243	95.647	87.365
Total		89676637	297878	100.000	100.000





1 PDA Multi 1/254nm 4nm


PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	23.119	8336004	143118	50.346	58.956
2	28.650	8221462	99637	49.654	41.044
Total		16557467	242754	100.000	100.000



1 PDA Multi 1/254nm 4nm

PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	23.580	2081930	38439	4.107	6.929
2	28.555	48614890	516341	95.893	93.071
Total		50696820	554780	100.000	100.000

HPLC chromatogram of series 6




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.870	10006861	424046	49.659	59.009
2	14.664	10144095	294567	50.341	40.991
Total		20150956	718613	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.971	203527	10187	0.373	0.720
2	14.527	54398967	1405393	99.627	99.280
Total		54602494	1415580	100.000	100.000



PDA Ch1 254nm 4nm



PeakTable


Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.739	26195821	870609	49.045	64.660
2	18.725	27216021	475823	50.955	35.340
Total		53411842	1346432	100.000	100.000



PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.893	7248667	268129	4.602	13.557
2	17.979	150245700	1709674	95.398	86.443
Total		157494367	1977802	100.000	100.000






PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.185	5549648	230324	50.222	66.656
2	15.807	5500612	115216	49.778	33.344
Total		11050260	345540	100.000	100.000



PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.251	2279569	93885	2.561	5.228
2	15.335	86744839	1701968	97.439	94.772
Total		89024408	1795853	100.000	100.000



PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.742	20324302	816991	50.166	59.265
2	12.990	20189988	561537	49.834	40.735
Total		40514290	1378527	100.000	100.000



PeakTable


PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.721	3045128	153690	5.950	10.366
2	12.827	48133054	1328934	94.050	89.634
Total		51178182	1482623	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.571	7869937	322549	49.774	68.479
2	26.457	7941395	148467	50.226	31.521
Total		15811332	471015	100.000	100.000



1 PDA Multi 1/254nm 4nm

PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.564	1135964	47598	1.512	3.455
2	26.317	74004318	1330245	98.488	96.545
Total		75140282	1377843	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.502	48844406	1115346	48.368	52.508
2	17.696	52141127	1008817	51.632	47.492
Total		100985532	2124163	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.993	1731336	50013	3.385	6.696
2	17.972	49418413	696899	96.615	93.304
Total		51149749	746912	100.000	100.000



PDA Ch1 254nm 4nm

PeakTable


Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.043	22518009	1161885	49.671	58.520
2	12.061	22815871	823555	50.329	41.480
Total		45333879	1985440	100.000	100.000



PDA Ch1 254nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.276	1032869	47438	2.477	3.503
2	11.979	40670646	1306802	97.523	96.497
Total		41703515	1354240	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.617	45441373	1423485	50.171	66.016
2	26.942	45132048	732802	49.829	33.984
Total		90573421	2156286	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.678	3395432	117706	5.115	10.338
2	26.263	62988646	1020902	94.885	89.662
Total		66384078	1138608	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.689	16314991	575372	49.586	58.088
2	18.703	16587695	415138	50.414	41.912
Total		32902686	990510	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.727	1213902	55146	1.738	3.587
2	18.515	68638423	1482084	98.262	96.413
Total		69852325	1537230	100.000	100.000




1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.045	14594339	418119	50.015	71.783
2	29.329	14585738	164360	49.985	28.217
Total		29180077	582478	100.000	100.000







1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.276	1325697	39580	5.590	14.063
2	29.566	22388263	241862	94.410	85.937
Total		23713960	281442	100.000	100.000






PeakTable

PDA Ch1 254nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.639	59216370	1540756	50.279	55.586
2	15.961	58560213	1231069	49.721	44.414
Total		117776583	2771825	100.000	100.000




PeakTable

PDA Ch1 254nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.805	1087696	35432	3.586	5.466
2	16.064	29241832	612826	96.414	94.534
Total		30329528	648258	100.000	100.000



PeakTable					
PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	21.622	8067307	151933	49.597	51.421
2	25.896	8198418	143535	50.403	48.579
Total		16265726	295469	100.000	100.000



PeakTable					
PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	21.994	27530	925	0.340	0.639
2	26.281	8066095	143847	99.660	99.361
Total		8093625	144772	100.000	100.000